<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10-PONE-RA-16236</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0009629</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology/Genetics of the Immune System</subject><subject>Immunology/Immunity to Infections</subject><subject>Infectious Diseases/Epidemiology and Control of Infectious Diseases</subject><subject>Infectious Diseases/HIV Infection and AIDS</subject><subject>Immunology/Genetics of the Immune System</subject><subject>Immunology/Immunity to Infections</subject><subject>Infectious Diseases/Epidemiology and Control of Infectious Diseases</subject><subject>Infectious Diseases/HIV Infection and AIDS</subject></subj-group></article-categories><title-group><article-title>Human Leukocyte Antigens and HIV Type 1 Viral Load in Early and Chronic Infection: Predominance of Evolving Relationships</article-title><alt-title alt-title-type="running-head">HLA and HIV-1 Viral Load</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Jianming</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Malhotra</surname><given-names>Rakhi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brill</surname><given-names>Ilene</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Liangyuan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Farmer</surname><given-names>Paul K.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mulenga</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hunter</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaslow</surname><given-names>Richard A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Vaccine Research Center, Emory University, Atlanta, Georgia, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Rwanda-Zambia HIV-1 Research Group, Lusaka, Zambia</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Nixon</surname><given-names>Douglas F.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California San Francisco, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>jtang@uab.edu</email> (JT); <email>rkaslow@uab.edu</email> (RAK)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: JT JM SA EH RK. Performed the experiments: WS LH. Analyzed the data: JT RM WS IB LH PKF. Contributed reagents/materials/analysis tools: JT RM IB PKF JM SA EH RK. Wrote the paper: JT SA EH RK.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2010</year></pub-date><volume>5</volume><issue>3</issue><elocation-id>e9629</elocation-id><history><date date-type="received"><day>11</day><month>2</month><year>2010</year></date><date date-type="accepted"><day>18</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>Tang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>During untreated, chronic HIV-1 infection, plasma viral load (VL) is a relatively stable quantitative trait that has clinical and epidemiological implications. Immunogenetic research has established various human genetic factors, especially human leukocyte antigen (HLA) variants, as independent determinants of VL set-point.</p></sec><sec><title>Methodology/Principal Findings</title><p>To identify and clarify HLA alleles that are associated with either transient or durable immune control of HIV-1 infection, we evaluated the relationships of HLA class I and class II alleles with VL among 563 seroprevalent Zambians (SPs) who were seropositive at enrollment and 221 seroconverters (SCs) who became seropositive during quarterly follow-up visits. After statistical adjustments for non-genetic factors (sex and age), two unfavorable alleles (A&#x0002a;3601 and DRB1&#x0002a;0102) were independently associated with high VL in SPs (<italic>p</italic>&#x0003c;0.01) but not in SCs. In contrast, favorable HLA variants, mainly A&#x0002a;74, B&#x0002a;13, B&#x0002a;57 (or Cw&#x0002a;18), and one <italic>HLA-A</italic> and <italic>HLA-C</italic> combination (A&#x0002a;30&#x0002b;Cw&#x0002a;03), dominated in SCs; their independent associations with low VL were reflected in regression beta estimates that ranged from &#x02212;0.47&#x000b1;0.23 to &#x02212;0.92&#x000b1;0.32 log<sub>10</sub> in SCs (<italic>p</italic>&#x0003c;0.05). Except for Cw&#x0002a;18, all favorable variants had diminishing or vanishing association with VL in SPs (<italic>p</italic>&#x02264;0.86).</p></sec><sec><title>Conclusions/Significance</title><p>Overall, each of the three HLA class I genes had at least one allele that might contribute to effective immune control, especially during the early course of HIV-1 infection. These observations can provide a useful framework for ongoing analyses of viral mutations induced by protective immune responses.</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Polymorphic human leukocyte antigen (HLA) molecules facilitate immune surveillance by presenting a wide spectrum of self and foreign antigens to T-cells and by serving as ligands for killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells. The extensive HLA allelic diversity <xref ref-type="bibr" rid="pone.0009629-Horton1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Schreuder1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Marsh1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-deBakker1">&#x0005b;4&#x0005d;</xref> reflects positive, negative, and balancing selections by myriad human pathogens <xref ref-type="bibr" rid="pone.0009629-Hughes1">&#x0005b;5&#x0005d;</xref>. In the context of human immunodeficiency virus type 1 (HIV-1) infection, multiple HLA class I alleles have been shown to differentially influence viral pathogenesis, often as a result of their selective targeting of viral epitopes for cytotoxic T-lymphocyte (CTL) responses <xref ref-type="bibr" rid="pone.0009629-Kiepiela1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Honeyborne1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Bansal1">&#x0005b;8&#x0005d;</xref>. Such CTL responses frequently and often rapidly induce viral immune escape, regardless of patient populations or HIV-1 subtypes (clades) <xref ref-type="bibr" rid="pone.0009629-Bansal1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Moore1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Bhattacharya1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Leslie1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Novitsky1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Treurnicht1">&#x0005b;14&#x0005d;</xref>. Viral adaptation to HLA class I-restricted, protective CTL responses can even reach fixation in a given population if the resulting viral mutations have little or no impact on viral fitness <xref ref-type="bibr" rid="pone.0009629-Kawashima1">&#x0005b;15&#x0005d;</xref>. In contrast, HIV-1 variants with CTL-driven mutations that are associated with substantial fitness costs can readily revert to the wild-type once they inhabit individuals who lack the CTL-inducing HLA alleles or their equivalents <xref ref-type="bibr" rid="pone.0009629-Leslie1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Leslie2">&#x0005b;16&#x0005d;</xref>. Understanding such intrinsic virus-HLA interplay at both the individual and population levels should help elucidate correlates of protection against HIV-1 infection, which are critical to the design of effective interventions.</p><p>Differential impact of HLA alleles on HIV-1 viral load (VL) was first observed among seroconverted men in the Multicenter AIDS Cohort Study <xref ref-type="bibr" rid="pone.0009629-Mann1">&#x0005b;17&#x0005d;</xref>, shortly after viral load was recognized as a clinically important outcome <xref ref-type="bibr" rid="pone.0009629-Mellors1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Saag1">&#x0005b;19&#x0005d;</xref>. More recently, at least three independent genome-wide association studies have confirmed that HLA genes are true quantitative trait loci (QTL) related to HIV-1 viremia <xref ref-type="bibr" rid="pone.0009629-Fellay1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Dalmasso1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Fellay2">&#x0005b;22&#x0005d;</xref>. These findings are consistent with other documented associations of HLA alleles or their supertypes with rates of HIV-1 disease progression (time to AIDS or CD4<sup>&#x0002b;</sup> T-cell depletion) <xref ref-type="bibr" rid="pone.0009629-Kaslow1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Catano1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Limou1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-LeClerc1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lazaryan1">&#x0005b;27&#x0005d;</xref>, although only a few HLA alleles have been considered as universally favorable or unfavorable.</p><p>In our own work, several HLA alleles and haplotypes have been associated with low (favorable) or high (unfavorable) VL in adult Zambians predominantly infected with HIV-1 clade C (HIV-1C) viruses <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>. HLA-B&#x0002a;57 as a universally favorable HLA variant <xref ref-type="bibr" rid="pone.0009629-Tang2">&#x0005b;29&#x0005d;</xref> was further associated with reduced rate (and incidence) of HIV-1 transmission from seropositive Zambians to their cohabiting partners <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>. To refine and expand these observations in our enlarged Zambian cohort, we have evaluated the potentially distinctive HLA relationships in seroconverters (SCs) and seroprevalent patients (SPs).</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Overall Characteristics of HIV-1 Seropositive Zambians</title><p>For this study, 784 HIV-1 seropositive Zambian adults consisted of 563 SPs who were seropositive at enrollment and 221 SCs who became seropositive during quarterly follow-up visits (<xref ref-type="table" rid="pone-0009629-t001"><bold>Table 1</bold></xref>). Most of them had the first known seropositive tests between 1996 and 2004. At the time of VL measurements, SPs had a median duration of follow-up (DOF) of 546 days, while SCs had a median duration of infection (DOI) of 229 days. DOF was defined as the time interval from enrollment to first plasma sample used for VL. DOI was the interval from the estimated time of HIV-1 infection (the midpoint between last seronegative test and first seropositive test) to the first plasma taken at least 63 days after infection. Except for a few outliers, DOF and DOI relative to VL measurements were &#x0003c;2,000 and &#x0003c;600 days, respectively (<xref ref-type="fig" rid="pone-0009629-g001"><bold>Figure 1</bold></xref>). Neither DOF nor DOI correlated with log<sub>10</sub> VL (<italic>p</italic>&#x02265;0.12). Between the two patient groups, statistically significant (<italic>p</italic>&#x02264;0.05) differences were seen for sex ratio, age, and the distribution of three VL categories previously shown to be highly predictive of viral transmission potential <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Fideli1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Tang4">&#x0005b;32&#x0005d;</xref>. The minor difference between SPs and SCs in log<sub>10</sub> VL was well within the boundary (0.30 log<sub>10</sub>) of biological and epidemiological relevance <xref ref-type="bibr" rid="pone.0009629-Saag1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Modjarrad1">&#x0005b;33&#x0005d;</xref>. For consistency with earlier work <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, sex and age group (&#x02265;40 versus &#x0003c;40 years) were retained as covariates (non-genetic factors) in subsequent association models.</p><fig id="pone-0009629-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009629.g001</object-id><label>Figure 1</label><caption><title>Distribution of HIV-1 viral load (VL) in the study population, with stratification by sex and serostatus at enrollment.</title><p>There is no linear correlation between duration of follow-up and log<sub>10</sub> VL in seroprevalent Zambians (<italic>p</italic>&#x02265;0.12) or duration of infection and log<sub>10</sub> VL in seroconverters (<italic>p</italic>&#x02265;0.56). In each panel, the projected slope and its 95&#x00025; confidence interval are shown in solid and dotted lines, respectively.</p></caption><graphic xlink:href="pone.0009629.g001"/></fig><table-wrap id="pone-0009629-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009629.t001</object-id><label>Table 1</label><caption><title>Characteristics of 563 Zambians who were HIV-1 seropositive at enrollment and 221 seroconverters who became seropositive during quarterly follow-up visits.</title></caption><alternatives><graphic id="pone-0009629-t001-1" xlink:href="pone.0009629.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristics</td><td align="left" rowspan="1" colspan="1">HIV-1 seroprevalents (SPs)</td><td align="left" rowspan="1" colspan="1">Seroconverters (SCs)</td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dates of seropositive tests</td><td align="left" rowspan="1" colspan="1">08/1999 (10/1996-03/2004)</td><td align="left" rowspan="1" colspan="1">10/2001 (03/1998-03/2004)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">DOF or DOI (in days)</td><td align="left" rowspan="1" colspan="1">546 (252&#x02013;962)</td><td align="left" rowspan="1" colspan="1">229 (134&#x02013;334)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex ratio: M/F</td><td align="left" rowspan="1" colspan="1">288/275 (1.05)</td><td align="left" rowspan="1" colspan="1">90/131 (0.69)</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (yrs, mean &#x000b1; SD)</td><td align="left" rowspan="1" colspan="1">31.0&#x000b1;7.8</td><td align="left" rowspan="1" colspan="1">28.8&#x000b1;7.4</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age group (n, &#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.064</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;40 yrs</td><td align="left" rowspan="1" colspan="1">108 (19.2)</td><td align="left" rowspan="1" colspan="1">30 (13.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;40 yrs</td><td align="left" rowspan="1" colspan="1">455 (80.8)</td><td align="left" rowspan="1" colspan="1">191 (86.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Viral load categories (n, &#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">Low (&#x0003c;10<sup>4</sup> copies/mL)</td><td align="left" rowspan="1" colspan="1">105 (18.7)</td><td align="left" rowspan="1" colspan="1">51 (23.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Medium (10<sup>4</sup>&#x02013;10<sup>5</sup>)</td><td align="left" rowspan="1" colspan="1">232 (41.2)</td><td align="left" rowspan="1" colspan="1">103 (46.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">High (&#x0003e;10<sup>5</sup> copies/mL)</td><td align="left" rowspan="1" colspan="1">226 (40.1)</td><td align="left" rowspan="1" colspan="1">67 (30.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">log<sub>10</sub> viral load (mean &#x000b1; SD)</td><td align="left" rowspan="1" colspan="1">4.71&#x000b1;0.78</td><td align="left" rowspan="1" colspan="1">4.54&#x000b1;0.77</td><td align="left" rowspan="1" colspan="1">0.006</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Dates (month/year) of seropositive tests, duration of follow-up (DOF, for SPs), and duration of infection (DOI, for SCs) are shown as median and interquartile range (in parentheses). The difference between patient groups is assessed using Mann-Whitney U test. All other comparisons between patient groups are based on Student's <italic>t</italic>-test (for quantitative measures) and &#x003c7;<sup>2</sup> test (for categorical measures). F &#x0200a;&#x0003d;&#x0200a; female; M &#x0200a;&#x0003d;&#x0200a; male; NA &#x0200a;&#x0003d;&#x0200a; not applicable; SD &#x0200a;&#x0003d;&#x0200a; standard deviation of the mean.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>HLA Class I Alleles and Their Common Haplotypes in Zambians</title><p>For the 784 HIV-1 seropositive Zambians, molecular genotyping for the three HLA class I genes (<italic>HLA-A</italic>, <italic>HLA-B</italic>, and <italic>HLA-C</italic>) resolved most alleles to their 4-digit (high resolution) designations while leaving some at their 2-digit (allele group) specificities. HLA class I allele groups with multiple common alleles were limited to A&#x0002a;02, A&#x0002a;30, A&#x0002a;68, B&#x0002a;14, B&#x0002a;15, B&#x0002a;42, B&#x0002a;44, B&#x0002a;57, B&#x0002a;58, Cw&#x0002a;02, Cw&#x0002a;03, and Cw&#x0002a;07. The overall frequencies of HLA class I alleles and haplotypes (local and extended) in the study population were highly comparable to those seen in 429 discordant couples (858 individuals, including 204 who remained HIV-1 seronegative) analyzed previously for heterosexual HIV-1 transmission <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>. One striking observation in our population was the high frequency (17&#x00025;) of B&#x0002a;1503-Cw&#x0002a;0210 (or B&#x0002a;15-Cw&#x0002a;02), a haplotype rarely reported elsewhere <xref ref-type="bibr" rid="pone.0009629-Cao1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Cano1">&#x0005b;36&#x0005d;</xref>. Eight HLA class I alleles (A&#x0002a;11, A&#x0002a;32, B&#x0002a;27, B&#x0002a;3502, B&#x0002a;3503, B&#x0002a;55, B&#x0002a;56, and Cw&#x0002a;05) reportedly associated with HIV-1 in populations of European ancestry <xref ref-type="bibr" rid="pone.0009629-Mann1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Fellay2">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Catano1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Dorak1">&#x0005b;37&#x0005d;</xref> were too rare to be assessed in Zambians (number of subjects ranged from one to 13).</p><p>Tests of linkage disequilibrium (LD) among HLA class I alleles focused on common allele groups seen in at least 16 individuals (&#x0223c;2&#x00025; of the study population). A total of 32 common, 2-locus haplotypes were identified (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s001">Table S1</xref></bold>). Correlation coefficients (<italic>r</italic>) in pairwise LD tests ranged from 0.17 to 0.97 (<italic>p</italic>&#x0003c;0.001 for all). Only two pairs of alleles, B&#x0002a;39 with Cw&#x0002a;12 plus B&#x0002a;42 with Cw&#x0002a;17, were considered as tagging for each other (<italic>r</italic><sup>2</sup>&#x0003e;0.75, <italic>p</italic>&#x0003c;1&#x000d7;10<sup>&#x02212;16</sup>). Accordingly, the vast majority of individual HLA class I alleles required independent testing in association analyses. Three common HLA class I combinations, A&#x0002a;23&#x0002b;B&#x0002a;14, A&#x0002a;23&#x0002b;Cw&#x0002a;07, and A&#x0002a;30&#x0002b;Cw&#x0002a;03, were also tested selectively because they were considered as probable haplotypes associated with HIV-1 VL in Zambians <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>.</p></sec><sec id="s2c"><title>HLA Class II Alleles and Their Common Haplotypes in Zambians</title><p>Alleles for two HLA class II genes, <italic>HLA-DRB1</italic> and <italic>HLA-DQB1</italic>, were fully resolved to their 4-digit designations in all but three of the 784 Zambians. Within the study population, 25 class II alleles found in at least 16 individuals qualified for formal association analyses. Strong linkage disequilibrium (LD) among alleles at these two neighboring class II loci allowed unambiguous assignment of 2-locus haplotypes in these subjects (probabilities &#x0003e;95&#x00025; for all), leading to the identification of 19 common haplotyes (<italic>r</italic>&#x0200a;&#x0003d;&#x0200a;0.22&#x02212;0.95, <italic>p</italic>&#x02264;0.01) (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s001">Table S1</xref></bold>). Only the neighboring alleles DRB1&#x0002a;0302 and DQB1&#x0002a;0402 were in sufficient LD to tag each other (<italic>r</italic><sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.89, <italic>p</italic>&#x0003c;1&#x000d7;10<sup>&#x02212;16</sup>). One common haplotype, DRB1&#x0002a;1301-DQB1&#x0002a;0501, appeared to be unique to the Zambian population. The frequency of the haplotype DRB1&#x0002a;1101-DQB1&#x0002a;0602 exceeded that of DRB1&#x0002a;1101-DQB1&#x0002a;0301 in Zambians; that excess has not been reported in other populations of African ancestry <xref ref-type="bibr" rid="pone.0009629-Hansen1">&#x0005b;38&#x0005d;</xref>. These overall allele and haplotype frequency patterns were similar to those seen in 584 Zambians (including 151 HIV-1 seronegatives) analyzed earlier for heterosexual HIV-1 transmission <xref ref-type="bibr" rid="pone.0009629-Tang4">&#x0005b;32&#x0005d;</xref>.</p></sec><sec id="s2d"><title>Analyses Using Categorical and Quantitative VL Measures</title><p>We used log<sub>10</sub> VL and two contrasting VL categories (high versus low) as alternative outcome measures in generalized linear models (GLMs) and logistic regression models to screen the effects of common HLA alleles and haplotypes, including fully resolved HLA class I alleles (e.g., A&#x0002a;6801, A&#x0002a;6802, B&#x0002a;3501, B&#x0002a;1302, B&#x0002a;3910, B&#x0002a;5801, and B&#x0002a;5802) implicated in earlier studies of native Africans or African-Americans <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Gao1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-MacDonald1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lazaryan2">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme2">&#x0005b;42&#x0005d;</xref>. The VL measure was first evaluated in SPs and SCs combined to improve statistical power (sample size) <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>. The comparison between the more extreme (categorical) VL outcomes excluded 335 patients (42.7&#x00025;) with intermediate VL in order to reduce the potential misclassification (overlapping) between patient groups <xref ref-type="bibr" rid="pone.0009629-LeClerc1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Hendel1">&#x0005b;43&#x0005d;</xref>.</p><p>In univariate GLMs, eight individual HLA variants and two <italic>HLA-A</italic> and <italic>HLA-C</italic> allele combinations were significantly associated with HIV-1 VL in this study population (<italic>p</italic>&#x02264;0.04) (<xref ref-type="table" rid="pone-0009629-t002"><bold>Table 2</bold></xref>). Five of these variants were favorable and five unfavorable, with the number of individuals carrying them ranging from 42 (5.4&#x00025;) to 116 (14.8&#x00025;). All variants from class I loci have shown similar associations elsewhere <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>. B&#x0002a;57 and Cw&#x0002a;18, which were in strong LD (<italic>r</italic>&#x0200a;&#x0003d;&#x0200a;0.75, <italic>p</italic>&#x0003c;1&#x000d7;10<sup>&#x02212;16</sup>), were the most favorable alleles (mean &#x003b2; estimates &#x02264;&#x02212;0.34 log<sub>10</sub>); A&#x0002a;36 and DRB1&#x0002a;0102 were most unfavorable (mean &#x003b2; close to 0.30 log<sub>10</sub> for both). These VL differences approached and usually exceeded the quantitative threshold (&#x000b1;0.30 log<sub>10</sub>, or &#x0223c;2-fold difference) considered biologically and epidemiologically significant <xref ref-type="bibr" rid="pone.0009629-Saag1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Modjarrad1">&#x0005b;33&#x0005d;</xref>. The weak association for Cw&#x0002a;16 (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.08) was explained by its LD (<italic>r</italic>&#x0200a;&#x0003d;&#x0200a;0.57, <italic>p</italic>&#x0003c;1&#x000d7;10<sup>&#x02212;16</sup>) with an established unfavorable allele B&#x0002a;45 (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.05).</p><table-wrap id="pone-0009629-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009629.t002</object-id><label>Table 2</label><caption><title>List of 11 HLA variants associated with HIV-1 viral load (VL) based on either generalized linear models (Series 1) or logistic regression analyses (Series 2).</title></caption><alternatives><graphic id="pone-0009629-t002-2" xlink:href="pone.0009629.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Series 1: all 784 Zambians</td><td colspan="3" align="left" rowspan="1">Series 2: high versus low VL</td></tr><tr><td align="left" rowspan="1" colspan="1">HLA variants</td><td align="left" rowspan="1" colspan="1">No. of subjects</td><td align="left" rowspan="1" colspan="1">Mean &#x003b2; &#x000b1; SE<sup>c</sup></td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td><td align="left" rowspan="1" colspan="1">No. of subjects</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)<sup>d</sup></td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;36</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1"><bold>0.26&#x000b1;0.08</bold></td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1"><bold>3.61 (1.66&#x02013;7.88)</bold></td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;74</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.21&#x000b1;0.08</bold></td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1"><bold>0.54 (0.30&#x02013;0.97)</bold></td><td align="left" rowspan="1" colspan="1">0.038</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;45<sup>e</sup></td><td align="left" rowspan="1" colspan="1">106</td><td align="left" rowspan="1" colspan="1"><bold>0.16&#x000b1;0.08</bold></td><td align="left" rowspan="1" colspan="1">0.043</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">1.62 (0.86&#x02013;3.04)</td><td align="left" rowspan="1" colspan="1">0.133</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;57</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.34&#x000b1;0.08</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1"><bold>0.31 (0.17&#x02013;0.58)</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;5802</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1"><bold>0.21</bold>&#x000b1;<bold>0.10</bold></td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">2.01 (0.92&#x02013;4.38)</td><td align="left" rowspan="1" colspan="1">0.080</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;81</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.30</bold>&#x000b1;<bold>0.11</bold></td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1"><bold>0.42 (0.20&#x02013;0.89)</bold></td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">Cw&#x0002a;16<sup>e</sup></td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">0.14&#x000b1;0.08</td><td align="left" rowspan="1" colspan="1">0.079</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">1.66 (0.88<bold>&#x02013;</bold>3.14)</td><td align="left" rowspan="1" colspan="1">0.121</td></tr><tr><td align="left" rowspan="1" colspan="1">Cw&#x0002a;18</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.37</bold>&#x000b1;<bold>0.07</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1"><bold>0.26 (0.15&#x02013;0.47)</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0102</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1"><bold>0.28&#x000b1;0.10</bold></td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1"><bold>3.24 (1.34&#x02013;7.86)</bold></td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;23&#x0002b;Cw&#x0002a;07</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1"><bold>0.22</bold>&#x000b1;<bold>0.10</bold></td><td align="left" rowspan="1" colspan="1">0.033</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">2.09 (0.85&#x02013;5.17)</td><td align="left" rowspan="1" colspan="1">0.111</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;30&#x0002b;Cw&#x0002a;03</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">&#x02212;<bold>0.33&#x000b1;0.12</bold></td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1"><bold>0.34 (0.13&#x02013;0.88)</bold></td><td align="left" rowspan="1" colspan="1">0.025</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Association analyses begin with a typical, cross-sectional study design to emphasize statistical power (Series 1). In Series 2, subjects with medium VL (10<sup>4</sup>&#x02013;10<sup>5</sup> copies/mL) are excluded, with the assumption that they may occasionally obscure the classification of patients with low and high VL (<xref ref-type="table" rid="pone-0009629-t001">Table 1</xref>). For consistency, sex and age are treated as covariates in each univariate analysis; statistically significant relationships (<italic>p</italic>&#x0003c;0.05) are shown in <bold>bold</bold>. CI &#x0200a;&#x0003d;&#x0200a; confidence interval; OR &#x0200a;&#x0003d;&#x0200a; odds ratio; SE &#x0200a;&#x0003d;&#x0200a; standard error.</p></fn></table-wrap-foot></table-wrap><p>Despite almost 43&#x00025; reduction in the total sample size, the logistic regression models provided confirmatory findings for seven of 10 HLA variants detected in GLMs (<xref ref-type="table" rid="pone-0009629-t002"><bold>Table 2</bold></xref>). The associations of B&#x0002a;45, B&#x0002a;5802, and A&#x0002a;23&#x0002b;Cw&#x0002a;07 were no longer nominally statistically significant (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.13, 0.08, and 0.11, respectively). Among the seven associations supported by logistic regression models, A&#x0002a;36 and DRB1&#x0002a;0102 were among the most unfavorable, while Cw&#x0002a;18 and B&#x0002a;57 were among the most favorable. These seven associations were further confirmed in alternative GLMs, where the parameter estimates improved for all (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s002">Table S2</xref></bold>). For all 10 HLA variants associated with VL using either outcome, their rankings based on respective beta estimates and on odds ratios had a strong correlation (Spearman &#x003c1;&#x0200a;&#x0003d;&#x0200a;0.99, <italic>p</italic>&#x0003c;0.0001). However, the same analytic approach failed to confirm the associations of 16 HLA variants with HIV-1 disease control, as previously reported for populations of European and African ancestry (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s003">Table S3</xref></bold>).</p></sec><sec id="s2e"><title>Stratified Analysis of SPs and SCs</title><p>For separate analyses of SPs and SCs, we first assessed the relationships across three categories of HIV-1 VL. Three alleles (A&#x0002a;36, A&#x0002a;74, and B&#x0002a;57) showed highly consistent effects on VL in both SPs and SCs (<italic>p</italic>&#x02264;0.02 in univariate Cochran-Armitage trend test in each patient group) (<xref ref-type="table" rid="pone-0009629-t003"><bold>Table 3</bold></xref>). Three associations (B&#x0002a;5802, Cw&#x0002a;18, and DRB1&#x0002a;0102) were restricted to SPs (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.02, &#x0003c;0.0001, and &#x0003c;0.01, respectively). Modest LD between A&#x0002a;29 and B&#x0002a;13 (<italic>r</italic>&#x0200a;&#x0003d;&#x0200a;0.27) (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s001">Table S1</xref></bold>) appeared to account for the association of A&#x0002a;29 in SCs (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.05): in the absence of B&#x0002a;13, the association of A&#x0002a;29 was no longer statistically significant (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.09).</p><table-wrap id="pone-0009629-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009629.t003</object-id><label>Table 3</label><caption><title>Distribution of 14 HLA variants in HIV-1 seroprevalent and seroconverted Zambians stratified by three levels of plasma viral load.</title></caption><alternatives><graphic id="pone-0009629-t003-3" xlink:href="pone.0009629.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="4" align="left" rowspan="1">Distribution (n, &#x00025;) in 563 seroprevalent Zambians (SPs)</td><td colspan="4" align="left" rowspan="1">Distribution (n, &#x00025;) in 221 seroconverters (SCs)</td></tr><tr><td align="left" rowspan="1" colspan="1">HLA variant</td><td align="left" rowspan="1" colspan="1">&#x0003c;10<sup>4</sup> (<italic>N</italic>&#x0200a;&#x0003d;&#x0200a;105)</td><td align="left" rowspan="1" colspan="1">10<sup>4</sup>&#x02013;10<sup>5</sup> (<italic>N</italic>&#x0200a;&#x0003d;&#x0200a;232)</td><td align="left" rowspan="1" colspan="1">&#x0003e;10<sup>5</sup> (<italic>N</italic>&#x0200a;&#x0003d;&#x0200a;226)</td><td align="left" rowspan="1" colspan="1"><italic>P</italic><sub>trend</sub></td><td align="left" rowspan="1" colspan="1">&#x0003c;10<sup>4</sup> (<italic>N</italic>&#x0200a;&#x0003d;&#x0200a;54)</td><td align="left" rowspan="1" colspan="1">10<sup>4</sup>&#x02013;10<sup>5</sup> (<italic>N</italic>&#x0200a;&#x0003d;&#x0200a;103)</td><td align="left" rowspan="1" colspan="1">&#x0003e;10<sup>5</sup> (<italic>N</italic>&#x0200a;&#x0003d;&#x0200a;67)</td><td align="left" rowspan="1" colspan="1"><italic>P</italic><sub>trend</sub></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;29</td><td align="left" rowspan="1" colspan="1">13 (12.4)</td><td align="left" rowspan="1" colspan="1">38 (16.4)</td><td align="left" rowspan="1" colspan="1">34 (15.0)</td><td align="left" rowspan="1" colspan="1">0.662</td><td align="left" rowspan="1" colspan="1">11 (21.6)</td><td align="left" rowspan="1" colspan="1">9 (8.7)</td><td align="left" rowspan="1" colspan="1">6 (9.0)</td><td align="left" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;36</td><td align="left" rowspan="1" colspan="1">7 (6.7)</td><td align="left" rowspan="1" colspan="1">25 (10.8)</td><td align="left" rowspan="1" colspan="1">31 (13.7)</td><td align="left" rowspan="1" colspan="1">0.057</td><td align="left" rowspan="1" colspan="1">2 (3.9)</td><td align="left" rowspan="1" colspan="1">16 (15.5)</td><td align="left" rowspan="1" colspan="1">14 (20.9)</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;74</td><td align="left" rowspan="1" colspan="1">21 (20.0)</td><td align="left" rowspan="1" colspan="1">37 (16.0)</td><td align="left" rowspan="1" colspan="1">28 (12.4)</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">9 (17.7)</td><td align="left" rowspan="1" colspan="1">10 (9.7)</td><td align="left" rowspan="1" colspan="1">3 (4.5)</td><td align="left" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;13</td><td align="left" rowspan="1" colspan="1">3 (2.9)</td><td align="left" rowspan="1" colspan="1">11 (4.7)</td><td align="left" rowspan="1" colspan="1">8 (3.5)</td><td align="left" rowspan="1" colspan="1">0.936</td><td align="left" rowspan="1" colspan="1">4 (7.8)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (3.0)</td><td align="left" rowspan="1" colspan="1">0.166</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;42</td><td align="left" rowspan="1" colspan="1">23 (21.9)</td><td align="left" rowspan="1" colspan="1">52 (22.4)</td><td align="left" rowspan="1" colspan="1">49 (21.7)</td><td align="left" rowspan="1" colspan="1">0.928</td><td align="left" rowspan="1" colspan="1">14 (27.5)</td><td align="left" rowspan="1" colspan="1">11 (10.7)</td><td align="left" rowspan="1" colspan="1">10 (14.9)</td><td align="left" rowspan="1" colspan="1">0.098</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;45</td><td align="left" rowspan="1" colspan="1">9 (8.6)</td><td align="left" rowspan="1" colspan="1">25 (10.8)</td><td align="left" rowspan="1" colspan="1">34 (15.0)</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">8 (15.7)</td><td align="left" rowspan="1" colspan="1">16 (15.5)</td><td align="left" rowspan="1" colspan="1">14 (20.9)</td><td align="left" rowspan="1" colspan="1">0.426</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;57</td><td align="left" rowspan="1" colspan="1">26 (24.8)</td><td align="left" rowspan="1" colspan="1">27 (11.6)</td><td align="left" rowspan="1" colspan="1">22 (9.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">7 (13.7)</td><td align="left" rowspan="1" colspan="1">11 (10.7)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;5802</td><td align="left" rowspan="1" colspan="1">5 (4.8)</td><td align="left" rowspan="1" colspan="1">8 (3.5)</td><td align="left" rowspan="1" colspan="1">23 (10.2)</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">5 (9.8)</td><td align="left" rowspan="1" colspan="1">14 (13.6)</td><td align="left" rowspan="1" colspan="1">10 (14.9)</td><td align="left" rowspan="1" colspan="1">0.427</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;8101</td><td align="left" rowspan="1" colspan="1">11 (10.5)</td><td align="left" rowspan="1" colspan="1">16 (6.9)</td><td align="left" rowspan="1" colspan="1">12 (5.3)</td><td align="left" rowspan="1" colspan="1">0.096</td><td align="left" rowspan="1" colspan="1">6 (11.8)</td><td align="left" rowspan="1" colspan="1">1 (1.0)</td><td align="left" rowspan="1" colspan="1">6 (9.0)</td><td align="left" rowspan="1" colspan="1">0.711</td></tr><tr><td align="left" rowspan="1" colspan="1">Cw&#x0002a;16</td><td align="left" rowspan="1" colspan="1">10 (9.5)</td><td align="left" rowspan="1" colspan="1">21 (9.1)</td><td align="left" rowspan="1" colspan="1">35 (15.5)</td><td align="left" rowspan="1" colspan="1">0.054</td><td align="left" rowspan="1" colspan="1">6 (11.8)</td><td align="left" rowspan="1" colspan="1">13 (12.6)</td><td align="left" rowspan="1" colspan="1">15 (22.4)</td><td align="left" rowspan="1" colspan="1">0.094</td></tr><tr><td align="left" rowspan="1" colspan="1">Cw&#x0002a;18</td><td align="left" rowspan="1" colspan="1">31 (29.5)</td><td align="left" rowspan="1" colspan="1">36 (15.5)</td><td align="left" rowspan="1" colspan="1">23 (10.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">8 (15.7)</td><td align="left" rowspan="1" colspan="1">8 (7.8)</td><td align="left" rowspan="1" colspan="1">5 (7.5)</td><td align="left" rowspan="1" colspan="1">0.154</td></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0102</td><td align="left" rowspan="1" colspan="1">2 (1.9)</td><td align="left" rowspan="1" colspan="1">14 (6.0)</td><td align="left" rowspan="1" colspan="1">23 (10.2)</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">5 (9.8)</td><td align="left" rowspan="1" colspan="1">8 (7.8)</td><td align="left" rowspan="1" colspan="1">8 (11.9)</td><td align="left" rowspan="1" colspan="1">0.641</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;23&#x0002b;Cw&#x0002a;07</td><td align="left" rowspan="1" colspan="1">5 (4.8)</td><td align="left" rowspan="1" colspan="1">15 (6.5)</td><td align="left" rowspan="1" colspan="1">21 (9.3)</td><td align="left" rowspan="1" colspan="1">0.113</td><td align="left" rowspan="1" colspan="1">2 (3.9)</td><td align="left" rowspan="1" colspan="1">8 (7.8)</td><td align="left" rowspan="1" colspan="1">5 (7.5)</td><td align="left" rowspan="1" colspan="1">0.481</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;30&#x0002b;Cw&#x0002a;03</td><td align="left" rowspan="1" colspan="1">7 (6.7)</td><td align="left" rowspan="1" colspan="1">15 (6.5)</td><td align="left" rowspan="1" colspan="1">7 (3.1)</td><td align="left" rowspan="1" colspan="1">0.106</td><td align="left" rowspan="1" colspan="1">6 (11.8)</td><td align="left" rowspan="1" colspan="1">5 (4.9)</td><td align="left" rowspan="1" colspan="1">2 (3.0)</td><td align="left" rowspan="1" colspan="1">0.052</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>HLA variants shown here have been confirmed in further analyses (generalized linear models, <xref ref-type="table" rid="pone-0009629-t004">Table 4</xref>) or reported in earlier studies of native Africans with HIV-1C infection <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lazaryan2">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme2">&#x0005b;42&#x0005d;</xref>.</p></fn></table-wrap-foot></table-wrap><p>Among HLA class I alleles associated with HIV-1 VL in either SPs or SCs or both groups, A&#x0002a;36 and B&#x0002a;5802 were unfavorable, while A&#x0002a;29, A&#x0002a;74, B&#x0002a;57, and Cw&#x0002a;18 were favorable; all of these were consistent with our earlier observations based on a smaller number of Zambians <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lazaryan2">&#x0005b;41&#x0005d;</xref>. Alleles implicated in other studies (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s003">Table S3</xref></bold>) <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lazaryan2">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme2">&#x0005b;42&#x0005d;</xref> could not be confirmed in logistic regression models (<xref ref-type="table" rid="pone-0009629-t003"><bold>Table 3</bold></xref>) or alternative models (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s003">Table S3</xref></bold>). Only B&#x0002a;57, represented primarily by B&#x0002a;5703 in Zambians, showed both strong internal consistency (between SPs and SCs) and unequivocal external corroboration <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Crawford1">&#x0005b;44&#x0005d;</xref>.</p><p>By GLM, including statistical adjustments for the effects of sex and age on HIV-1 VL, only B&#x0002a;57 (favorable) and B&#x0002a;5802 (unfavorable) were associated with log<sub>10</sub> HIV-1 VL in both SPs and SCs (<italic>p</italic>&#x02264;0.05) (<xref ref-type="table" rid="pone-0009629-t004"><bold>Table 4</bold></xref>). Six additional associations were seen only in SPs: unfavorable for A&#x0002a;36, B&#x0002a;45, and DRB1&#x0002a;0102 (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.004, 0.010, and 0.002, respectively) and favorable for B&#x0002a;8101, Cw&#x0002a;18, and A&#x0002a;30&#x0002b;Cw&#x0002a;03 (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.025, &#x0003c;0.0001, and 0.034, respectively). In addition, A&#x0002a;29 and A&#x0002a;74 were favorable only in SCs (<italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.015 and &#x0003c;0.001, respectively).</p><table-wrap id="pone-0009629-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009629.t004</object-id><label>Table 4</label><caption><title>Quantitative impact of 14 HLA variants on log<sub>10</sub> HIV-1 viral load in two groups of Zambians.</title></caption><alternatives><graphic id="pone-0009629-t004-4" xlink:href="pone.0009629.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Tests in 563 seroprevalent Zambians (SPs)</td><td colspan="3" align="left" rowspan="1">Tests in 221 seroconverters (SCs)</td></tr><tr><td align="left" rowspan="1" colspan="1">HLA variants</td><td align="left" rowspan="1" colspan="1">No. of subjects</td><td align="left" rowspan="1" colspan="1">&#x003b2; &#x000b1; SE<sup>b</sup></td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td><td align="left" rowspan="1" colspan="1">No. of subjects</td><td align="left" rowspan="1" colspan="1">&#x003b2; &#x000b1; SE<sup>b</sup></td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;29</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">0.07&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.392</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.42</bold>&#x000b1;<bold>0.17</bold></td><td align="left" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;36</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1"><bold>0.29&#x000b1;0.10</bold></td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">0.21&#x000b1;0.16</td><td align="left" rowspan="1" colspan="1">0.189</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;74</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">&#x02212;0.15&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.086</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.59&#x000b1;0.18</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;13</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">&#x02212;0.03&#x000b1;0.16</td><td align="left" rowspan="1" colspan="1">0.860</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.78</bold>&#x000b1;<bold>0.33</bold></td><td align="left" rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;42</td><td align="left" rowspan="1" colspan="1">124</td><td align="left" rowspan="1" colspan="1">&#x02212;0.01&#x000b1;0.08</td><td align="left" rowspan="1" colspan="1">0.905</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">&#x02212;0.14&#x000b1;0.15</td><td align="left" rowspan="1" colspan="1">0.360</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;45</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1"><bold>0.25&#x000b1;0.09</bold></td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">&#x02212;0.04&#x000b1;0.15</td><td align="left" rowspan="1" colspan="1">0.804</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;57</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.28&#x000b1;0.09</bold></td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.62&#x000b1;0.20</bold></td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;5802</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1"><bold>0.28&#x000b1;0.13</bold></td><td align="left" rowspan="1" colspan="1">0.027</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1"><bold>0.33&#x000b1;0.16</bold></td><td align="left" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;8101</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.27&#x000b1;0.12</bold></td><td align="left" rowspan="1" colspan="1">0.025</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">&#x02212;0.29&#x000b1;0.23</td><td align="left" rowspan="1" colspan="1">0.204</td></tr><tr><td align="left" rowspan="1" colspan="1">Cw&#x0002a;16</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">0.16&#x000b1;0.10</td><td align="left" rowspan="1" colspan="1">0.096</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">0.02&#x000b1;0.15</td><td align="left" rowspan="1" colspan="1">0.886</td></tr><tr><td align="left" rowspan="1" colspan="1">Cw&#x0002a;18</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.39&#x000b1;0.08</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">&#x02212;0.30&#x000b1;0.19</td><td align="left" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0102</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1"><bold>0.38&#x000b1;0.12</bold></td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02&#x000b1;0.19</td><td align="left" rowspan="1" colspan="1">0.894</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;23&#x0002b;Cw&#x0002a;07</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">0.22&#x000b1;0.12</td><td align="left" rowspan="1" colspan="1">0.072</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">0.31&#x000b1;0.22</td><td align="left" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;30&#x0002b;Cw&#x0002a;03</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">&#x02212;<bold>0.30&#x000b1;0.14</bold></td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">&#x02212;0.45&#x000b1;0.25</td><td align="left" rowspan="1" colspan="1">0.071</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>HLA variants are the same as those presented in <xref ref-type="table" rid="pone-0009629-t003">Table 3</xref>. The parameter estimates (mean beta and standard error, SE) are statistically adjusted for sex and age; numbers in <bold>bold</bold> have adjusted <italic>p</italic> values&#x02264;0.05.</p></fn></table-wrap-foot></table-wrap><p>Biologically and epidemiologically meaningful differences (0.30 log<sub>10</sub>) in VL were observed for only three most favorable HLA alleles (A&#x0002a;29, A&#x0002a;74, and B&#x0002a;57) in SCs, their regression beta estimates ranged from &#x02212;0.42&#x000b1;0.17 to &#x02212;0.62&#x000b1;0.20 log<sub>10</sub> (<xref ref-type="table" rid="pone-0009629-t004"><bold>Table 4</bold></xref>). However, in SPs the respective estimates diminished by at least 0.30 log<sub>10</sub> (a two-fold difference). Although strong LD between B&#x0002a;57 and Cw&#x0002a;18 (<italic>r</italic>&#x0200a;&#x0003d;&#x0200a;0.74 and 0.77 in SPs and SCs, respectively, <italic>p</italic>&#x0003c;1&#x000d7;10<sup>&#x02212;16</sup> for both) would have predicted similar impact of these two alleles in both patient groups, the impact of B&#x0002a;57 appeared stronger in SCs. B&#x0002a;13 (all B&#x0002a;1302 in this cohort) was clearly favorable in SCs (&#x02212;0.78&#x000b1;0.33 log<sub>10</sub>, <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.02), but its effect vanished in SPs (0.03&#x000b1;0.16 log<sub>10</sub>, <italic>p</italic>&#x0200a;&#x0003d;&#x0200a;0.86).</p><p>The effect sizes of the unfavorable A&#x0002a;36 and B&#x0002a;5802 varied little between SPs and SCs. For B&#x0002a;45 and DRB1&#x0002a;0102, the unfavorable effect observed in SPs was absent in SCs (<xref ref-type="table" rid="pone-0009629-t004"><bold>Table 4</bold></xref>). Again, the same analytic approach did not confirm or imply the involvement of other HLA alleles of major interest (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s003">Table S3</xref></bold>) &#x0005b;<xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lazaryan2">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme2">&#x0005b;42&#x0005d;</xref>.</p></sec><sec id="s2f"><title>Multivariable Analyses of HLA Variants and log<sub>10</sub> VL</title><p>In a reduced multivariable model for SPs, A&#x0002a;36 and DRB1&#x0002a;0102 continued to show unfavorable association with VL (&#x0002b;0.25 and &#x0002b;0.38 log<sub>10</sub>, respectively, <italic>p</italic>&#x0003c;0.01 for both) (<xref ref-type="table" rid="pone-0009629-t005"><bold>Table 5</bold></xref>), while at least five HLA alleles and one HLA combination were retained as additional cofactors (adjusted <italic>p</italic>&#x0003c;0.05 for all) (<xref ref-type="table" rid="pone-0009629-t005"><bold>Table 5</bold></xref>). Based on their respective effect sizes (adjusted beta estimates), B&#x0002a;57, B&#x0002a;8101, and A&#x0002a;30&#x0002b;Cw&#x0002a;03 had similarly favorable impact on VL (&#x0223c;&#x02212;0.30 log<sub>10</sub>), and A&#x0002a;74 showed more modest impact (&#x02212;0.20&#x000b1;0.08 log<sub>10</sub>). Cw&#x0002a;18 could replace B&#x0002a;57 and B&#x0002a;8101 as an independent factor (<italic>p</italic>&#x0003c;0.0001), but the association of B&#x0002a;57 and B&#x0002a;8101 was no longer statistically significant when the three variants were forced into the same model (results not shown).</p><table-wrap id="pone-0009629-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009629.t005</object-id><label>Table 5</label><caption><title>Multifactorial influences on log<sub>10</sub> viral load (VL) in HIV-1 seroprevalent Zambians (SPs) and seroconverters (SCs).</title></caption><alternatives><graphic id="pone-0009629-t005-5" xlink:href="pone.0009629.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Reduced model 1: 563 SPs</td><td colspan="3" align="left" rowspan="1">Reduced model 2: 221 SCs</td></tr><tr><td align="left" rowspan="1" colspan="1">Covariates</td><td align="left" rowspan="1" colspan="1">No. of subjects</td><td align="left" rowspan="1" colspan="1">&#x003b2; &#x000b1; SE</td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td><td align="left" rowspan="1" colspan="1">No. of subjects</td><td align="left" rowspan="1" colspan="1">&#x003b2; &#x000b1; SE</td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex &#x0200a;&#x0003d;&#x0200a; F</td><td align="left" rowspan="1" colspan="1">275</td><td align="left" rowspan="1" colspan="1">&#x02212;0.53&#x000b1;0.06</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">&#x02212;0.41&#x000b1;0.11</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x02265;40 yrs</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">&#x02212;0.08&#x000b1;0.08</td><td align="left" rowspan="1" colspan="1">0.344</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">0.36&#x000b1;0.15</td><td align="left" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;36</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">0.25&#x000b1;0.10</td><td align="left" rowspan="1" colspan="1">0.009</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;74</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">&#x02212;0.20&#x000b1;0.08</td><td align="left" rowspan="1" colspan="1">0.017</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">&#x02212;0.59&#x000b1;0.17</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">&#x02212;0.92&#x000b1;0.32</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>B&#x0002a;57</bold></td><td align="left" rowspan="1" colspan="1"><bold>75</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.30&#x000b1;0.09</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.001</bold></td><td align="left" rowspan="1" colspan="1"><bold>18</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.60&#x000b1;0.19</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.002</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x0002a;8101</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">&#x02212;0.28&#x000b1;0.12</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Cw&#x0002a;18</bold></td><td align="left" rowspan="1" colspan="1"><bold>90</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.39&#x000b1;0.08</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1"><bold>21</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x02212;0.37&#x000b1;0.18</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.041</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">A&#x0002a;30&#x0002b;Cw&#x0002a;03</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">&#x02212;0.32&#x000b1;0.14</td><td align="left" rowspan="1" colspan="1">0.020</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">&#x02212;0.47&#x000b1;0.23</td><td align="left" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0102</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">0.38&#x000b1;0.12</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>The parameter estimates (mean beta and standard error, SE) are adjusted for all factors retained in each model. Because of strong LD (see text), B&#x0002a;57 and Cw&#x0002a;18 (in <bold>bold</bold>) are entered into separate models for both SPs and SCs.</p></fn></table-wrap-foot></table-wrap><p>In SCs, favorable HLA class I alleles and one 2-allele combination dominated the independent effects, with mean beta estimates ranging from &#x02212;0.47 to &#x02212;0.92 log<sub>10</sub> (&#x0223c;3.0- to 8.3-fold) (<italic>p</italic>&#x0003c;0.05). These effects were ranked as B&#x0002a;13&#x0003e;B&#x0002a;57&#x0003e;A&#x0002a;74&#x0003e;(A&#x0002a;30&#x0002b;Cw&#x0002a;03) or B&#x0002a;13&#x0003e;A&#x0002a;74&#x0003e;Cw&#x0002a;18&#x0003e;(A&#x0002a;30&#x0002b;Cw&#x0002a;03) when B&#x0002a;57 was replaced Cw&#x0002a;18 in the reduced multivariable model. The adjusted effect sizes attributed to all five favorable HLA variants in aggregate exceeded the effect sizes for age and sex. In contrast to the model for SPs, a model for SCs that included both B&#x0002a;57 and Cw&#x0002a;18 indicated a non-significant association with Cw&#x0002a;18 (data not shown).</p><p>In further assessment of favorable and unfavorable HLA variants retained in the multivariable models (<xref ref-type="table" rid="pone-0009629-t005"><bold>Table 5</bold></xref>), it was evident that they did not segregate by a) specific <italic>HLA-A</italic> and <italic>HLA-B</italic> supertypes, including those that have been added or refined recently <xref ref-type="bibr" rid="pone.0009629-Sidney1">&#x0005b;45&#x0005d;</xref>, b) HLA serological groups (properties as alloantigens), or c) relative frequency that might introduce allelic bias in homozygosity and heterozygosity within the study population.</p></sec></sec><sec id="s3"><title>Discussion</title><p>Our expanded analyses of VL as a quantitative trait (log<sub>10</sub> copy number) or as a categorical outcome measure in adult Zambians confirmed most of the favorable and unfavorable HLA associations that we previously reported <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>; this study also yielded three new, internally consistent findings. First, the associations of most of the favorable HLA class I alleles were more readily detected in seroconverters (SCs) than in seroprevalent subjects (SPs), even though SPs outnumbered SCs by 2-fold. HLA-A&#x0002a;74, B&#x0002a;57 (or Cw&#x0002a;18), and A&#x0002a;30&#x0002b;Cw&#x0002a;03 were clearly favorable; B&#x0002a;13 also appeared favorable in the few SCs with this allele. For each of these variants, its biologically and epidemiologically meaningful impact on VL either substantially diminished or totally vanished in SPs. Second, individual alleles and haplotypes at HLA class II loci were not prominently associated with altered viremia at the population level. Only one class II allele (DRB1&#x0002a;0102) was associated with high VL, and only in SPs. No other HLA class II allele or haplotype, including any previously reported to be associated with HIV-1 transmission or acquisition &#x0005b;<xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lazaryan2">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme2">&#x0005b;42&#x0005d;</xref>, showed appreciable impact on VL in either patient group. Third, an alternative study design that included only about 60&#x00025; of the population with the two extreme categories of VL yielded very similar results (<bold><xref ref-type="supplementary-material" rid="pone.0009629.s002">Table S2</xref></bold>). In resource-limited settings that require concentration on patients with extreme outcomes <xref ref-type="bibr" rid="pone.0009629-LeClerc1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Hendel1">&#x0005b;43&#x0005d;</xref>, considerable savings in cost may be achieved with relatively little loss of power, especially for exploratory studies of genetic determinants.</p><p>Plasma VL during untreated, chronic HIV-1 infection reflects an equilibrium between viral replication and immunologically mediated viral clearance. Population-based studies have clearly established the predictive value of VL for heterosexual HIV-1 transmission <xref ref-type="bibr" rid="pone.0009629-Fideli1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Quinn1">&#x0005b;46&#x0005d;</xref> as well as time to AIDS, especially in Caucasian males <xref ref-type="bibr" rid="pone.0009629-Mellors1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Lyles1">&#x0005b;47&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Mellors2">&#x0005b;48&#x0005d;</xref>. Although our initial work indicated that variants from all three HLA class I genes were associated with VL in chronically infected Zambians <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, similar work based on a South African cohort has shown that <italic>HLA-B</italic> allele played the most dominant role <xref ref-type="bibr" rid="pone.0009629-Kiepiela2">&#x0005b;35&#x0005d;</xref>. In the same South African cohort, several favorable HLA alleles (B&#x0002a;42, B&#x0002a;57, B&#x0002a;5801, and B&#x0002a;8101) were further predictive of CD4<sup>&#x0002b;</sup> T-cell slope over a 2-year follow-up period <xref ref-type="bibr" rid="pone.0009629-Brumme2">&#x0005b;42&#x0005d;</xref>. Our analyses here did not support the favorable association of B&#x0002a;42, although A&#x0002a;29 as a marginally favorable allele in Zambians (seroconverters only) showed weak LD with B&#x0002a;42. Two other <italic>HLA-A</italic> alleles (A&#x0002a;36 as unfavorable and A&#x0002a;74 as favorable) had even stronger associations, none of which could be explained by effects of their accompanying <italic>HLA-B</italic> and <italic>HLA-C</italic> alleles. Both alleles have been confirmed in recent analyses of African-Americans (unpublished results, available from RAK and JT). Thus, although the influences of multiple <italic>HLA-B</italic> variants on HIV-1 pathogenesis and evolution have been more readily detected and confirmed, several <italic>HLA-A</italic> alleles can exert comparable effects.</p><p><italic>HLA-B</italic> and <italic>HLA-C</italic> genes are located in a genomic segment (the beta block) rarely disrupted by recombination hot spots <xref ref-type="bibr" rid="pone.0009629-Dawkins1">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Yunis1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Miretti1">&#x0005b;51&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Smith1">&#x0005b;52&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Romero1">&#x0005b;53&#x0005d;</xref>. As a result, the associations of two <italic>HLA-C</italic> alleles (Cw&#x0002a;16 as unfavorable and Cw&#x0002a;18 as favorable) with VL in Zambians could be partially or completely explained by their strong LD with <italic>HLA-B</italic> alleles: B&#x0002a;45 for Cw&#x0002a;16 and B&#x0002a;57 plus B&#x0002a;8101 for Cw&#x0002a;18. However, as we noted earlier <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>, experimental evidence does suggest that Cw&#x0002a;1801 is able to present viral epitopes for cytotoxic T-lymphocyte (CTL) responses, which might account for its relatively durable impact on VL. Identification of one favorable A-C combination (A&#x0002a;30&#x0002b;Cw&#x0002a;03) further supported the role of <italic>HLA-C</italic> alleles in HIV-1 infection, because none of these alleles individually had a clear association with VL. Assuming that alleles at <italic>HLA-C</italic> and <italic>HLA-A</italic> can act in concert to confer genetic advantage during HIV-1 infection (or disadvantage in other settings), differences in peptide-binding and in <italic>HLA-C</italic> allelic expression can offer two plausible explanations <xref ref-type="bibr" rid="pone.0009629-Fellay1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Thomas1">&#x0005b;54&#x0005d;</xref>. Of note, environmental factors can further complicate the genotype-phenotype relationships by influencing gene expression in leukocytes <xref ref-type="bibr" rid="pone.0009629-Idaghdour1">&#x0005b;55&#x0005d;</xref>.</p><p>HLA class II molecules specialize in presenting exogenous antigens for immune surveillance by CD4<sup>&#x0002b;</sup> T-helper (T<sub>H</sub>) cells. Their peptide-binding grooves can be loaded with protein degradation products (13&#x02013;25 amino-acid residues) generated in the lysosome. CD4<sup>&#x0002b;</sup> T-cells that effectively respond to HIV-1 antigens can facilitate immune control through cytokines and T-cell-dependent antibody responses, but activated T<sub>H</sub> cells, especially those specific to HIV-1 antigens, are lost rapidly because they are preferentially targeted by the virus <xref ref-type="bibr" rid="pone.0009629-Douek1">&#x0005b;56&#x0005d;</xref>. Striking a balance between the two functions can be difficult. Recent work has identified 33 HIV-1 epitopes recognized by CD4<sup>&#x0002b;</sup> T-cells in patients with chronic HIV-1C infection <xref ref-type="bibr" rid="pone.0009629-Ramduth1">&#x0005b;57&#x0005d;</xref>. Direct interactions between HIV-1 and HLA class II molecules have also been reported <xref ref-type="bibr" rid="pone.0009629-Cantin1">&#x0005b;58&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Cantin2">&#x0005b;59&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-StumptnerCuvelette1">&#x0005b;60&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Schindler1">&#x0005b;61&#x0005d;</xref>. Among individual HLA class II alleles, DRB1&#x0002a;1301 has been seen as a favorable allele in various populations <xref ref-type="bibr" rid="pone.0009629-Kaslow1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Tang4">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Malhotra1">&#x0005b;62&#x0005d;</xref>. Our analyses here failed to confirm any of the previously reported HLA class II alleles or haplotypes. Instead, DRB1&#x0002a;0102 was associated with higher VL, but only in SPs. The relationship counters to the hypothesized early involvement of class II molecules, before the precipitous loss of CD4<sup>&#x0002b;</sup> T-cells. The largely inconclusive findings for HLA class II alleles and haplotypes might reflect their promiscuity in antigen presentation.</p><p>Within the context of HIV-1C infection, the Zambian cohort has produced some of the first evidence that HLA factors can mediate HIV-1 VL as well as heterosexual transmission <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Tang4">&#x0005b;32&#x0005d;</xref>. Identification of favorable HLA factors in this cohort is particularly encouraging, as relatively few HLA alleles have unequivocal (consensus) effects in various investigations, especially in the era of highly active antiretroviral therapy <xref ref-type="bibr" rid="pone.0009629-Tang2">&#x0005b;29&#x0005d;</xref>. For the few favorable HLA class I alleles confirmed in the Zambian, several have known or predicted HIV-1 epitopes <xref ref-type="bibr" rid="pone.0009629-Brumme1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Honeyborne2">&#x0005b;63&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Geldmacher1">&#x0005b;64&#x0005d;</xref>. For example, epitope-specific functional correlation is well documented for B&#x0002a;57 <xref ref-type="bibr" rid="pone.0009629-Crawford1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Goepfert1">&#x0005b;65&#x0005d;</xref>. B&#x0002a;13 (all B&#x0002a;1302 in Zambians) is another class I allele repeatedly observed as favorable <xref ref-type="bibr" rid="pone.0009629-Honeyborne1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme2">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Harrer1">&#x0005b;66&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme3">&#x0005b;67&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Emu1">&#x0005b;68&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Prado1">&#x0005b;69&#x0005d;</xref>. The impact of the favorable HLA class I alleles and haplotypes on VL was consistently more prominent in SCs than in SPs, suggesting that immune control mediated by favorable alleles like B&#x0002a;57 and B&#x0002a;13 diminish with time, most likely due to viral immune escape and accumulation of compensatory mutations <xref ref-type="bibr" rid="pone.0009629-Leslie1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Brumme1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Yu1">&#x0005b;70&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Karlsson1">&#x0005b;71&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Crawford2">&#x0005b;72&#x0005d;</xref>. Further association of favorable HLA alleles (B&#x0002a;57 and Cw&#x0002a;18) with reduced rates and incidences of heterosexual HIV-1 transmission in the Zambian cohort was also most apparent during the early follow-up period <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>. Continuing efforts to monitor the evolution of viral epitopes targeted by favorable HLA variants should provide critical guidance for HIV-1 vaccine design and clinical trials.</p><p>When expressed as a log<sub>10</sub> value (a continuous variable), VL differences greater than 0.30 log<sub>10</sub> (&#x0223c;2-fold) are often considered biologically and epidemiologically significant <xref ref-type="bibr" rid="pone.0009629-Saag1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Modjarrad1">&#x0005b;33&#x0005d;</xref>. By our analyses, at least four favorable HLA class I alleles and one favorable combination independently conferred biologically and epidemiologically important impact on VL in SCs (<xref ref-type="table" rid="pone-0009629-t005"><bold>Table 5</bold></xref>). By contrast, the absence of advantageous class II variants highlights the importance of CTL and likely natural killer (NK) cell activities mediated by the three HLA class I genes. In particular, one or both of these pathways must be effective in controlling HIV-1 infection, since VL set-point is typically reached within the first nine weeks after HIV-1 infection <xref ref-type="bibr" rid="pone.0009629-Brenchley1">&#x0005b;73&#x0005d;</xref>, before the debut of high-affinity neutralizing antibody responses <xref ref-type="bibr" rid="pone.0009629-Pellegrin1">&#x0005b;74&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kulkarni1">&#x0005b;75&#x0005d;</xref>. Again, collection of longitudinal VL and viral sequencing data from SCs will help determine the timing and scope of viral immune escape, as already reported for HIV-1 <italic>gag</italic> variants <xref ref-type="bibr" rid="pone.0009629-Novitsky1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Crawford1">&#x0005b;44&#x0005d;</xref>. In addition, ongoing elucidation of KIR genotypes should set the stage for thorough, systematic evaluation of HLA-KIR interaction, which is the second and potentially critical pathway by which HLA class I alleles may regulate HIV-1 infection.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and Methods</title><sec id="s4a"><title>Ethics Statement</title><p>This study complied with the human experimentation guidelines of the United States Department of Health and Human Services, and all enrolled patients provided written informed consent. The work presented here was further approved by the Institutional Review Boards at University of Alabama at Birmingham, under Protocols X051108005 and X071119002.</p></sec><sec id="s4b"><title>Study Population, HIV-1 Viral Load (VL), and HLA Genotyping</title><p>Beginning in 1995, HIV-1 seropositive Zambians were recruited and followed by the Rwanda/Zambia HIV-1 Research Group in Lusaka, Zambia. Procedures for quarterly medical examination, voluntary counseling and testing, and viral sequencing have been described elsewhere <xref ref-type="bibr" rid="pone.0009629-Fideli1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Goepfert1">&#x0005b;65&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Trask1">&#x0005b;76&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Allen1">&#x0005b;77&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Kempf1">&#x0005b;78&#x0005d;</xref>. Measurements of plasma HIV-1 VL (RNA copies) were made in most cases with the Roche Amplicor 1.0 assay (Roche Diagnostics Systems Inc., Branchburg, NJ), which had a lower limit of detection (LLD) of 400 RNA copies per ml of plasma. HLA genotyping relied on a combination of PCR-based methods, including PCR with sequence-specific primers (SSP) (Dynal/Invitrogen, Brown Deer, WI), automated sequence-specific oligonucleotide (SSO) probe hybridization (Innogenetics, Alpharetta, GA), and sequencing-based typing (SBT) (Abbott Molecular, Inc., Des Plaines, IL) using capillary electrophoresis and the ABI 3130xl DNA Analyzer (Applied Biosystems, Foster City, CA) <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Li1">&#x0005b;79&#x0005d;</xref>. HLA alleles were resolved to the first four digits, which correspond to distinct protein products designated by the World Health Organization Nomenclature Committee for Factors of the HLA System <xref ref-type="bibr" rid="pone.0009629-Robinson1">&#x0005b;80&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Holdsworth1">&#x0005b;81&#x0005d;</xref>.</p></sec><sec id="s4c"><title>Computational Assignment of Local and Extended HLA Haplotypes</title><p>Using the expectation-maximization (EM) algorithm in SAS Genetics (SAS Institute, Cary, NC), common HLA class I B-C haplotypes were assigned for <italic>HLA-B</italic> and <italic>HLA-C</italic> alleles because of their known, strong linkage disequilibrium (LD) in the study population <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>. DRB1-DQB1 haplotypes were assigned for <italic>HLA-DRB1</italic> and <italic>HLA-DQB1</italic> alleles in the same way and for the same reason <xref ref-type="bibr" rid="pone.0009629-Tang4">&#x0005b;32&#x0005d;</xref>. Assignments of these 2-locus (local) haplotypes helped to distinguish allelic from haplotypic effects. Assignments of extended haplotypes were assessed by relative LD (D') and correlation coefficients (<italic>r</italic>). In a given individual, simultaneous assignments of two haplotypes with a statistical probability &#x02265;70&#x00025; by the EM algorithm were considered reliable. Individuals with unreliable haplotype assignments (probabilities &#x0003c;70&#x00025;) were excluded from formal testing of haplotypic associations.</p></sec><sec id="s4d"><title>Descriptive Statistics</title><p>The overall characteristics of HIV-1 seroprevalent Zambians (SPs) and seroconverters (SCs) with complete HLA genotyping were summarized in <xref ref-type="table" rid="pone-0009629-t001"><bold>Table 1</bold></xref>. Differences between the two patient groups were assessed using Mann-Whitney U test (fro duration of infection or follow-up), Student's <italic>t</italic>-test (for age and log<sub>10</sub> viral load), and &#x003c7;<sup>2</sup> test (for sex ratio, age group, and three categories of viral load).</p></sec><sec id="s4e"><title>Analyses of HLA Variants in Relation to HIV-1 VL</title><p>The statistical approach to association analysis followed the strategies established in other related work <xref ref-type="bibr" rid="pone.0009629-Tang1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Tang3">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Fideli1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Tang5">&#x0005b;82&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Song1">&#x0005b;83&#x0005d;</xref>, except that a) enlarged sample size (improved statistical power) facilitated separate analyses of 563 SPs versus 221 SCs, b) 56 individuals (32 SPs and 24 SCs) representing couples with unlinked viruses were retained in analyses because HLA genotyping had already been completed before non-identity of the virus in suspected recipients (seroconverters) was established; c) 19 SPs from cohabiting couples with short (&#x0003c;9 mth) follow-up were also included; d) 18 patients (15 SPs and 3 SCs) with VL less than the lower limit of detection (400 copies/mL) were excluded; e) several univariate models were presented in order to facilitate meta-analysis; f) software packages in SAS was updated to version 9.2 (SAS Institute), and g) results sorted in SAS were used to produce graphs using GraphPad Prism version 5.0 (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/prism/Prism.htm">http://www.graphpad.com/prism/Prism.htm</ext-link>). Summary statistics in association analyses included: 1) proportional odds ratio (pOR) and 95&#x00025; confidence intervals (CIs); 2) regression beta estimates, expressed as means and standard errors (SE), and 3) univariate and multivariable (adjusted) <italic>p</italic> values. A <italic>p</italic> value&#x02264;0.050 was considered statistically significant because most HLA alleles and haplotypes highlighted in this work have been implicated in earlier studies. The overall emphasis was on biologically and epidemiologically significant (&#x0003e;0.30 log<sub>10</sub>) differences in VL <xref ref-type="bibr" rid="pone.0009629-Saag1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009629-Modjarrad1">&#x0005b;33&#x0005d;</xref>.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0009629.s001"><label>Table S1</label><caption><p>HLA class I and class II alleles and haplotypes found in at least 16 out of 784 adult Zambians.</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0009629.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0009629.s002"><label>Table S2</label><caption><p>HLA variants associated with log<sub>10</sub> HIV-1 viral load (VL) based on alternative generalized linear models.</p><p>(0.05 MB DOC)</p></caption><media xlink:href="pone.0009629.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0009629.s003"><label>Table S3</label><caption><p>Dismissal of 16 candidate HLA variants reported in earlier studies and common in Zambians.</p><p>(0.07 MB DOC)</p></caption><media xlink:href="pone.0009629.s003.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank staff and study participants in the Zambia-Emory HIV-1 Research Project for their valuable contributions to various aspects of this study. We are also grateful to Ulgen Fideli and Amanda Tichacek for data management, to Dongning He, Yirong Ni, and Wenshuo Shao for technical assistance, and to Yun Joo Yun for structuring SAS programming templates.</p></ack><ref-list><title>References</title><ref id="pone.0009629-Horton1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>R</given-names></name><name><surname>Wilming</surname><given-names>L</given-names></name><name><surname>Rand</surname><given-names>V</given-names></name><name><surname>Lovering</surname><given-names>RC</given-names></name><name><surname>Bruford</surname><given-names>EA</given-names></name><etal/></person-group><year>2004</year><article-title>Gene map of the extended human MHC.</article-title><source>Nat Rev Genet</source><volume>5</volume><fpage>889</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">15573121</pub-id></mixed-citation></ref><ref id="pone.0009629-Schreuder1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreuder</surname><given-names>GM</given-names></name><name><surname>Hurley</surname><given-names>CK</given-names></name><name><surname>Marsh</surname><given-names>SG</given-names></name><name><surname>Lau</surname><given-names>M</given-names></name><name><surname>Fernandez-Vina</surname><given-names>MA</given-names></name><etal/></person-group><year>2005</year><article-title>HLA dictionary 2004: summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens.</article-title><source>Hum Immunol</source><volume>66</volume><fpage>170</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">15695003</pub-id></mixed-citation></ref><ref id="pone.0009629-Marsh1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>SG</given-names></name><name><surname>Albert</surname><given-names>ED</given-names></name><name><surname>Bodmer</surname><given-names>WF</given-names></name><name><surname>Bontrop</surname><given-names>RE</given-names></name><name><surname>Dupont</surname><given-names>B</given-names></name><etal/></person-group><year>2005</year><article-title>Nomenclature for factors of the HLA system, 2004.</article-title><source>Hum Immunol</source><volume>66</volume><fpage>571</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">15935895</pub-id></mixed-citation></ref><ref id="pone.0009629-deBakker1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><name><surname>Sabeti</surname><given-names>PC</given-names></name><name><surname>Miretti</surname><given-names>MM</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC.</article-title><source>Nat Genet</source><volume>38</volume><fpage>1166</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">16998491</pub-id></mixed-citation></ref><ref id="pone.0009629-Hughes1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>AL</given-names></name></person-group><year>2002</year><article-title>Natural selection and the diversification of vertebrate immune effectors.</article-title><source>Immunol Rev</source><volume>190</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">12493013</pub-id></mixed-citation></ref><ref id="pone.0009629-Kiepiela1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiepiela</surname><given-names>P</given-names></name><name><surname>Ngumbela</surname><given-names>K</given-names></name><name><surname>Thobakgale</surname><given-names>C</given-names></name><name><surname>Ramduth</surname><given-names>D</given-names></name><name><surname>Honeyborne</surname><given-names>I</given-names></name><etal/></person-group><year>2007</year><article-title>CD8&#x0002b; T-cell responses to different HIV proteins have discordant associations with viral load.</article-title><source>Nat Med</source><volume>13</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">17173051</pub-id></mixed-citation></ref><ref id="pone.0009629-Honeyborne1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honeyborne</surname><given-names>I</given-names></name><name><surname>Prendergast</surname><given-names>A</given-names></name><name><surname>Pereyra</surname><given-names>F</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name><name><surname>Crawford</surname><given-names>H</given-names></name><etal/></person-group><year>2007</year><article-title>Control of human immunodeficiency virus type 1 is associated with HLA-B&#x0002a;13 and targeting of multiple gag-specific CD8&#x0002b; T-cell epitopes.</article-title><source>J Virol</source><volume>81</volume><fpage>3667</fpage><lpage>3672</lpage><pub-id pub-id-type="pmid">17251285</pub-id></mixed-citation></ref><ref id="pone.0009629-Bansal1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>A</given-names></name><name><surname>Yue</surname><given-names>L</given-names></name><name><surname>Conway</surname><given-names>J</given-names></name><name><surname>Yusim</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.</article-title><source>AIDS</source><volume>21</volume><fpage>2387</fpage><lpage>2397</lpage><pub-id pub-id-type="pmid">18025875</pub-id></mixed-citation></ref><ref id="pone.0009629-Moore1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>CB</given-names></name><name><surname>John</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>IR</given-names></name><name><surname>Christiansen</surname><given-names>FT</given-names></name><name><surname>Witt</surname><given-names>CS</given-names></name><etal/></person-group><year>2002</year><article-title>Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.</article-title><source>Science</source><volume>296</volume><fpage>1439</fpage><lpage>1443</lpage><pub-id pub-id-type="pmid">12029127</pub-id></mixed-citation></ref><ref id="pone.0009629-Bhattacharya1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Daniels</surname><given-names>M</given-names></name><name><surname>Heckerman</surname><given-names>D</given-names></name><name><surname>Foley</surname><given-names>B</given-names></name><name><surname>Frahm</surname><given-names>N</given-names></name><etal/></person-group><year>2007</year><article-title>Founder effects in the assessment of HIV polymorphisms and HLA allele associations.</article-title><source>Science</source><volume>315</volume><fpage>1583</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">17363674</pub-id></mixed-citation></ref><ref id="pone.0009629-Leslie1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>AJ</given-names></name><name><surname>Pfafferott</surname><given-names>KJ</given-names></name><name><surname>Chetty</surname><given-names>P</given-names></name><name><surname>Draenert</surname><given-names>R</given-names></name><name><surname>Addo</surname><given-names>MM</given-names></name><etal/></person-group><year>2004</year><article-title>HIV evolution: CTL escape mutation and reversion after transmission.</article-title><source>Nat Med</source><volume>10</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">14770175</pub-id></mixed-citation></ref><ref id="pone.0009629-Brumme1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brumme</surname><given-names>ZL</given-names></name><name><surname>Brumme</surname><given-names>CJ</given-names></name><name><surname>Heckerman</surname><given-names>D</given-names></name><name><surname>Korber</surname><given-names>BT</given-names></name><name><surname>Daniels</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1.</article-title><source>PLoS Pathog</source><volume>3</volume><fpage>e94</fpage><pub-id pub-id-type="pmid">17616974</pub-id></mixed-citation></ref><ref id="pone.0009629-Novitsky1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novitsky</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Margolin</surname><given-names>L</given-names></name><name><surname>Baca</surname><given-names>J</given-names></name><name><surname>Kebaabetswe</surname><given-names>L</given-names></name><etal/></person-group><year>2009</year><article-title>Timing constraints of <italic>in vivo</italic> Gag mutations during primary HIV-1 subtype C infection.</article-title><source>PLoS One</source><volume>4</volume><fpage>e7727</fpage><pub-id pub-id-type="pmid">19890401</pub-id></mixed-citation></ref><ref id="pone.0009629-Treurnicht1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treurnicht</surname><given-names>FK</given-names></name><name><surname>Seoighe</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>DP</given-names></name><name><surname>Wood</surname><given-names>N</given-names></name><name><surname>Abrahams</surname><given-names>MR</given-names></name><etal/></person-group><year>2010</year><article-title>Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure.</article-title><source>Virology</source><volume>396</volume><fpage>213</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">19913270</pub-id></mixed-citation></ref><ref id="pone.0009629-Kawashima1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawashima</surname><given-names>Y</given-names></name><name><surname>Pfafferott</surname><given-names>K</given-names></name><name><surname>Frater</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>P</given-names></name><name><surname>Payne</surname><given-names>R</given-names></name><etal/></person-group><year>2009</year><article-title>Adaptation of HIV-1 to human leukocyte antigen class I.</article-title><source>Nature</source><volume>458</volume><fpage>641</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">19242411</pub-id></mixed-citation></ref><ref id="pone.0009629-Leslie2"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>A</given-names></name><name><surname>Kavanagh</surname><given-names>D</given-names></name><name><surname>Honeyborne</surname><given-names>I</given-names></name><name><surname>Pfafferott</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><etal/></person-group><year>2005</year><article-title>Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.</article-title><source>J Exp Med</source><volume>201</volume><fpage>891</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">15781581</pub-id></mixed-citation></ref><ref id="pone.0009629-Mann1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>DL</given-names></name><name><surname>Garner</surname><given-names>RP</given-names></name><name><surname>Dayhoff</surname><given-names>DE</given-names></name><name><surname>Cao</surname><given-names>K</given-names></name><name><surname>Fernandez-Vina</surname><given-names>MA</given-names></name><etal/></person-group><year>1998</year><article-title>Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans.</article-title><source>J Infect Dis</source><volume>178</volume><fpage>1799</fpage><lpage>1802</lpage><pub-id pub-id-type="pmid">9815238</pub-id></mixed-citation></ref><ref id="pone.0009629-Mellors1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellors</surname><given-names>JW</given-names></name><name><surname>Rinaldo</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>RM</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><etal/></person-group><year>1996</year><article-title>Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.</article-title><source>Science</source><volume>272</volume><fpage>1167</fpage><lpage>1170</lpage><pub-id pub-id-type="pmid">8638160</pub-id></mixed-citation></ref><ref id="pone.0009629-Saag1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saag</surname><given-names>MS</given-names></name><name><surname>Holodniy</surname><given-names>M</given-names></name><name><surname>Kuritzkes</surname><given-names>DR</given-names></name><name><surname>O'Brien</surname><given-names>WA</given-names></name><name><surname>Coombs</surname><given-names>R</given-names></name><etal/></person-group><year>1996</year><article-title>HIV viral load markers in clinical practice.</article-title><source>Nat Med</source><volume>2</volume><fpage>625</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">8640545</pub-id></mixed-citation></ref><ref id="pone.0009629-Fellay1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellay</surname><given-names>J</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Colombo</surname><given-names>S</given-names></name><name><surname>Ledergerber</surname><given-names>B</given-names></name><etal/></person-group><year>2007</year><article-title>A whole-genome association study of major determinants for host control of HIV-1.</article-title><source>Science</source><volume>317</volume><fpage>944</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">17641165</pub-id></mixed-citation></ref><ref id="pone.0009629-Dalmasso1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalmasso</surname><given-names>C</given-names></name><name><surname>Carpentier</surname><given-names>W</given-names></name><name><surname>Meyer</surname><given-names>L</given-names></name><name><surname>Rouzioux</surname><given-names>C</given-names></name><name><surname>Goujard</surname><given-names>C</given-names></name><etal/></person-group><year>2008</year><article-title>Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.</article-title><source>PLoS One</source><volume>3</volume><fpage>e3907</fpage><pub-id pub-id-type="pmid">19107206</pub-id></mixed-citation></ref><ref id="pone.0009629-Fellay2"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellay</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Colombo</surname><given-names>S</given-names></name><name><surname>Ledergerber</surname><given-names>B</given-names></name><etal/></person-group><year>2009</year><article-title>Common genetic variation and the control of HIV-1 in humans.</article-title><source>PLoS Genet</source><volume>5</volume><fpage>e1000791</fpage><pub-id pub-id-type="pmid">20041166</pub-id></mixed-citation></ref><ref id="pone.0009629-Kaslow1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaslow</surname><given-names>RA</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Apple</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>L</given-names></name><name><surname>Munoz</surname><given-names>A</given-names></name><etal/></person-group><year>1996</year><article-title>Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.</article-title><source>Nat Med</source><volume>2</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">8597949</pub-id></mixed-citation></ref><ref id="pone.0009629-Catano1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catano</surname><given-names>G</given-names></name><name><surname>Kulkarni</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Marconi</surname><given-names>VC</given-names></name><name><surname>Agan</surname><given-names>BK</given-names></name><etal/></person-group><year>2008</year><article-title>HIV-1 disease-influencing effects associated with <italic>ZNRD1</italic>, <italic>HCP5</italic> and <italic>HLA-C</italic> alleles are attributable mainly to either <italic>HLA-A10</italic> or <italic>HLA-B&#x0002a;57</italic> alleles.</article-title><source>PLoS ONE</source><volume>3</volume><fpage>e3636</fpage><pub-id pub-id-type="pmid">18982067</pub-id></mixed-citation></ref><ref id="pone.0009629-Limou1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limou</surname><given-names>S</given-names></name><name><surname>Le Clerc</surname><given-names>S</given-names></name><name><surname>Coulonges</surname><given-names>C</given-names></name><name><surname>Carpentier</surname><given-names>W</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><etal/></person-group><year>2009</year><article-title>Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).</article-title><source>J Infect Dis</source><volume>199</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">19115949</pub-id></mixed-citation></ref><ref id="pone.0009629-LeClerc1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Clerc</surname><given-names>S</given-names></name><name><surname>Limou</surname><given-names>S</given-names></name><name><surname>Coulonges</surname><given-names>C</given-names></name><name><surname>Carpentier</surname><given-names>W</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><etal/></person-group><year>2009</year><article-title>Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03).</article-title><source>J Infect Dis</source><volume>200</volume><fpage>1194</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">19754311</pub-id></mixed-citation></ref><ref id="pone.0009629-Lazaryan1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaryan</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Lobashevsky</surname><given-names>E</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><etal/></person-group><year>2010</year><article-title>Human leukocyte antigen class I supertypes and HIV-1 control in African Americans.</article-title><source>J Virol: in press</source></mixed-citation></ref><ref id="pone.0009629-Tang1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Lobashevsky</surname><given-names>E</given-names></name><name><surname>Myracle</surname><given-names>AD</given-names></name><name><surname>Fideli</surname><given-names>U</given-names></name><etal/></person-group><year>2002</year><article-title>Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.</article-title><source>J Virol</source><volume>76</volume><fpage>8276</fpage><lpage>8284</lpage><pub-id pub-id-type="pmid">12134033</pub-id></mixed-citation></ref><ref id="pone.0009629-Tang2"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Kaslow</surname><given-names>RA</given-names></name></person-group><year>2003</year><article-title>The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy.</article-title><source>AIDS</source><volume>17</volume><fpage>S51</fpage><lpage>S60</lpage><pub-id pub-id-type="pmid">15080180</pub-id></mixed-citation></ref><ref id="pone.0009629-Tang3"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>W</given-names></name><name><surname>Yoo</surname><given-names>YJ</given-names></name><name><surname>Brill</surname><given-names>I</given-names></name><name><surname>Mulenga</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples.</article-title><source>J Immunol</source><volume>181</volume><fpage>2626</fpage><lpage>2635</lpage><pub-id pub-id-type="pmid">18684953</pub-id></mixed-citation></ref><ref id="pone.0009629-Fideli1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fideli</surname><given-names>US</given-names></name><name><surname>Allen</surname><given-names>S</given-names></name><name><surname>Musunda</surname><given-names>R</given-names></name><name><surname>Trask</surname><given-names>S</given-names></name><name><surname>Hahn</surname><given-names>B</given-names></name><etal/></person-group><year>2001</year><article-title>Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 (HIV-1) in Africa.</article-title><source>AIDS Res Hum Retroviruses</source><volume>17</volume><fpage>901</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">11461676</pub-id></mixed-citation></ref><ref id="pone.0009629-Tang4"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Penman-Aguilar</surname><given-names>A</given-names></name><name><surname>Lobashevsky</surname><given-names>E</given-names></name><name><surname>Allen</surname><given-names>S</given-names></name><name><surname>Kaslow</surname><given-names>R</given-names></name><etal/></person-group><year>2004</year><article-title><italic>HLA-DRB1</italic> and -<italic>DQB1</italic> alleles and haplotypes in Zambian couples and their associations with heterosexual transmission of human immunodeficiency virus type 1.</article-title><source>J Infect Dis</source><volume>189</volume><fpage>1696</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">15116308</pub-id></mixed-citation></ref><ref id="pone.0009629-Modjarrad1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modjarrad</surname><given-names>K</given-names></name><name><surname>Chamot</surname><given-names>E</given-names></name><name><surname>Vermund</surname><given-names>SH</given-names></name></person-group><year>2008</year><article-title>Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.</article-title><source>AIDS</source><volume>22</volume><fpage>2179</fpage><lpage>2185</lpage><pub-id pub-id-type="pmid">18832881</pub-id></mixed-citation></ref><ref id="pone.0009629-Cao1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>K</given-names></name><name><surname>Hollenbach</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Chopek</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.</article-title><source>Hum Immunol</source><volume>62</volume><fpage>1009</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">11543903</pub-id></mixed-citation></ref><ref id="pone.0009629-Kiepiela2"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiepiela</surname><given-names>P</given-names></name><name><surname>Leslie</surname><given-names>AJ</given-names></name><name><surname>Honeyborne</surname><given-names>I</given-names></name><name><surname>Ramduth</surname><given-names>D</given-names></name><name><surname>Thobakgale</surname><given-names>C</given-names></name><etal/></person-group><year>2004</year><article-title>Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.</article-title><source>Nature</source><volume>432</volume><fpage>769</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">15592417</pub-id></mixed-citation></ref><ref id="pone.0009629-Cano1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cano</surname><given-names>P</given-names></name><name><surname>Klitz</surname><given-names>W</given-names></name><name><surname>Mack</surname><given-names>SJ</given-names></name><name><surname>Maiers</surname><given-names>M</given-names></name><name><surname>Marsh</surname><given-names>SG</given-names></name><etal/></person-group><year>2007</year><article-title>Common and well-documented HLA alleles: Report of the ad-hoc committee of the American Society for Histocompatiblity and Immunogenetics.</article-title><source>Hum Immunol</source><volume>68</volume><fpage>392</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">17462507</pub-id></mixed-citation></ref><ref id="pone.0009629-Dorak1"><label>37</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Dorak</surname><given-names>MT</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Coutinho</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>J</given-names></name><etal/></person-group><comment>Association of HLA-B22 with increased plasma HIV-1 RNA concentration and accelerated disease progression to AIDS in Caucasian cohorts.; 2002 February 24-28.; Seattle, WA</comment></mixed-citation></ref><ref id="pone.0009629-Hansen1"><label>38</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JA</given-names></name></person-group><year>2006</year><article-title>Immunobiology of the Human MHC.</article-title><size units="page"/><comment>Seattle, Washington</comment></mixed-citation></ref><ref id="pone.0009629-Gao1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Nelson</surname><given-names>GW</given-names></name><name><surname>Karacki</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>MP</given-names></name><name><surname>Phair</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.</article-title><source>N Engl J Med</source><volume>344</volume><fpage>1668</fpage><lpage>1675</lpage><pub-id pub-id-type="pmid">11386265</pub-id></mixed-citation></ref><ref id="pone.0009629-MacDonald1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>KS</given-names></name><name><surname>Matukas</surname><given-names>L</given-names></name><name><surname>Embree</surname><given-names>JE</given-names></name><name><surname>Fowke</surname><given-names>K</given-names></name><name><surname>Kimani</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design.</article-title><source>Immunol Lett</source><volume>79</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">11595302</pub-id></mixed-citation></ref><ref id="pone.0009629-Lazaryan2"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaryan</surname><given-names>A</given-names></name><name><surname>Lobashevsky</surname><given-names>E</given-names></name><name><surname>Mulenga</surname><given-names>J</given-names></name><name><surname>Karita</surname><given-names>E</given-names></name><name><surname>Allen</surname><given-names>S</given-names></name><etal/></person-group><year>2006</year><article-title>Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans.</article-title><source>J Virol</source><volume>80</volume><fpage>6056</fpage><lpage>6060</lpage><pub-id pub-id-type="pmid">16731944</pub-id></mixed-citation></ref><ref id="pone.0009629-Brumme2"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brumme</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Nair</surname><given-names>K</given-names></name><name><surname>Brumme</surname><given-names>C</given-names></name><name><surname>de Pierres</surname><given-names>C</given-names></name><etal/></person-group><year>2009</year><article-title>Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa.</article-title><source>Clin Infect Dis</source><volume>49</volume><fpage>956</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">19663693</pub-id></mixed-citation></ref><ref id="pone.0009629-Hendel1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendel</surname><given-names>H</given-names></name><name><surname>Caillat-Zucman</surname><given-names>S</given-names></name><name><surname>Lebuanec</surname><given-names>H</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><etal/></person-group><year>1999</year><article-title>New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS.</article-title><source>J Immunol</source><volume>162</volume><fpage>6942</fpage><lpage>6946</lpage><pub-id pub-id-type="pmid">10352317</pub-id></mixed-citation></ref><ref id="pone.0009629-Crawford1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>H</given-names></name><name><surname>Lumm</surname><given-names>W</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name><name><surname>Schaefer</surname><given-names>M</given-names></name><name><surname>Boeras</surname><given-names>D</given-names></name><etal/></person-group><year>2009</year><article-title>Evolution of HLA-B&#x0002a;5703 HIV-1 escape mutations in HLA-B&#x0002a;5703-positive individuals and their transmission recipients.</article-title><source>J Exp Med</source><volume>206</volume><fpage>909</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">19307327</pub-id></mixed-citation></ref><ref id="pone.0009629-Sidney1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Frahm</surname><given-names>N</given-names></name><name><surname>Brander</surname><given-names>C</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>HLA class I supertypes: a revised and updated classification.</article-title><source>BMC Immunol</source><volume>9</volume><fpage>1</fpage><comment>(doi: 10.1186/1471-2172-1189-1181)</comment><pub-id pub-id-type="pmid">18211710</pub-id></mixed-citation></ref><ref id="pone.0009629-Quinn1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>TC</given-names></name><name><surname>Wawer</surname><given-names>MJ</given-names></name><name><surname>Sewankambo</surname><given-names>N</given-names></name><name><surname>Serwadda</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><year>2000</year><article-title>Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.</article-title><source>N Engl J Med</source><volume>342</volume><fpage>921</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">10738050</pub-id></mixed-citation></ref><ref id="pone.0009629-Lyles1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyles</surname><given-names>RH</given-names></name><name><surname>Munoz</surname><given-names>A</given-names></name><name><surname>Yamashita</surname><given-names>TE</given-names></name><name><surname>Bazmi</surname><given-names>H</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name><etal/></person-group><year>2000</year><article-title>Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study.</article-title><source>J Infect Dis</source><volume>181</volume><fpage>872</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">10720507</pub-id></mixed-citation></ref><ref id="pone.0009629-Mellors2"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellors</surname><given-names>JW</given-names></name><name><surname>Margolick</surname><given-names>JB</given-names></name><name><surname>Phair</surname><given-names>JP</given-names></name><name><surname>Rinaldo</surname><given-names>CR</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name><etal/></person-group><year>2007</year><article-title>Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection.</article-title><source>JAMA</source><volume>297</volume><fpage>2349</fpage><lpage>2350</lpage><pub-id pub-id-type="pmid">17551128</pub-id></mixed-citation></ref><ref id="pone.0009629-Dawkins1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawkins</surname><given-names>R</given-names></name><name><surname>Leelayuwat</surname><given-names>C</given-names></name><name><surname>Gaudieri</surname><given-names>S</given-names></name><name><surname>Tay</surname><given-names>G</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><etal/></person-group><year>1999</year><article-title>Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease.</article-title><source>Immunol Rev</source><volume>167</volume><fpage>275</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">10319268</pub-id></mixed-citation></ref><ref id="pone.0009629-Yunis1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunis</surname><given-names>EJ</given-names></name><name><surname>Larsen</surname><given-names>CE</given-names></name><name><surname>Fernandez-Vina</surname><given-names>M</given-names></name><name><surname>Awdeh</surname><given-names>ZL</given-names></name><name><surname>Romero</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>Inheritable variable sizes of DNA stretches in the human MHC: conserved extended haplotypes and their fragments or blocks.</article-title><source>Tissue Antigens</source><volume>62</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12859592</pub-id></mixed-citation></ref><ref id="pone.0009629-Miretti1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miretti</surname><given-names>MM</given-names></name><name><surname>Walsh</surname><given-names>EC</given-names></name><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Delgado</surname><given-names>M</given-names></name><name><surname>Griffiths</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms.</article-title><source>Am J Hum Genet</source><volume>76</volume><fpage>634</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">15747258</pub-id></mixed-citation></ref><ref id="pone.0009629-Smith1"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>WP</given-names></name><name><surname>Vu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>SS</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name><name><surname>Zhao</surname><given-names>LP</given-names></name><etal/></person-group><year>2006</year><article-title>Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes.</article-title><source>Genomics</source><volume>87</volume><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">16434165</pub-id></mixed-citation></ref><ref id="pone.0009629-Romero1"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>V</given-names></name><name><surname>Larsen</surname><given-names>CE</given-names></name><name><surname>Duke-Cohan</surname><given-names>JS</given-names></name><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Romero</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Genetic fixity in the human major histocompatibility complex and block size diversity in the class I region including HLA-E.</article-title><source>BMC Genet</source><volume>8</volume><fpage>14</fpage><pub-id pub-id-type="pmid">17430593</pub-id></mixed-citation></ref><ref id="pone.0009629-Thomas1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Apps</surname><given-names>R</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Male</surname><given-names>V</given-names></name><etal/></person-group><year>2009</year><article-title>HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of <italic>HLA-C</italic>.</article-title><source>Nat Genet</source><volume>41</volume><fpage>1290</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">19935663</pub-id></mixed-citation></ref><ref id="pone.0009629-Idaghdour1"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idaghdour</surname><given-names>Y</given-names></name><name><surname>Czika</surname><given-names>W</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Visscher</surname><given-names>PM</given-names></name><etal/></person-group><year>2009</year><article-title>Geographical genomics of human leukocyte gene expression variation in southern Morocco.</article-title><source>Nat Genet</source></mixed-citation></ref><ref id="pone.0009629-Douek1"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douek</surname><given-names>D</given-names></name><name><surname>Brenchley</surname><given-names>J</given-names></name><name><surname>Betts</surname><given-names>M</given-names></name><name><surname>Ambrozak</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>B</given-names></name><etal/></person-group><year>2002</year><article-title>HIV preferentially infects HIV-specific CD4&#x0002b; T cells.</article-title><source>Nature</source><volume>417</volume><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">11986671</pub-id></mixed-citation></ref><ref id="pone.0009629-Ramduth1"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramduth</surname><given-names>D</given-names></name><name><surname>Day</surname><given-names>CL</given-names></name><name><surname>Thobakgale</surname><given-names>CF</given-names></name><name><surname>Mkhwanazi</surname><given-names>NP</given-names></name><name><surname>de Pierres</surname><given-names>C</given-names></name><etal/></person-group><year>2009</year><article-title>Immunodominant HIV-1 CD4&#x0002b; T cell epitopes in chronic untreated clade C HIV-1 infection.</article-title><source>PLoS ONE</source><volume>4</volume><fpage>e5013</fpage><pub-id pub-id-type="pmid">19352428</pub-id></mixed-citation></ref><ref id="pone.0009629-Cantin1"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantin</surname><given-names>R</given-names></name><name><surname>Fortin</surname><given-names>JF</given-names></name><name><surname>Lamontagne</surname><given-names>G</given-names></name><name><surname>Tremblay</surname><given-names>M</given-names></name></person-group><year>1997</year><article-title>The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells.</article-title><source>Blood</source><volume>90</volume><fpage>1091</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">9242540</pub-id></mixed-citation></ref><ref id="pone.0009629-Cantin2"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantin</surname><given-names>R</given-names></name><name><surname>Fortin</surname><given-names>JF</given-names></name><name><surname>Lamontagne</surname><given-names>G</given-names></name><name><surname>Tremblay</surname><given-names>M</given-names></name></person-group><year>1997</year><article-title>The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.</article-title><source>J Virol</source><volume>71</volume><fpage>1922</fpage><lpage>1930</lpage><pub-id pub-id-type="pmid">9032323</pub-id></mixed-citation></ref><ref id="pone.0009629-StumptnerCuvelette1"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumptner-Cuvelette</surname><given-names>P</given-names></name><name><surname>Morchoisne</surname><given-names>S</given-names></name><name><surname>Dugast</surname><given-names>M</given-names></name><name><surname>Le Gall</surname><given-names>S</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><etal/></person-group><year>2001</year><article-title>HIV-1 Nef impairs MHC class II antigen presentation and surface expression.</article-title><source>Proc Natl Acad Sci USA</source><volume>98</volume><fpage>12144</fpage><lpage>12149</lpage><pub-id pub-id-type="pmid">11593029</pub-id></mixed-citation></ref><ref id="pone.0009629-Schindler1"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>M</given-names></name><name><surname>Wurfl</surname><given-names>S</given-names></name><name><surname>Benaroch</surname><given-names>P</given-names></name><name><surname>Greenough</surname><given-names>TC</given-names></name><name><surname>Daniels</surname><given-names>R</given-names></name><etal/></person-group><year>2003</year><article-title>Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles.</article-title><source>J Virol</source><volume>77</volume><fpage>10548</fpage><lpage>10556</lpage><pub-id pub-id-type="pmid">12970439</pub-id></mixed-citation></ref><ref id="pone.0009629-Malhotra1"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>U</given-names></name><name><surname>Holte</surname><given-names>S</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Berrey</surname><given-names>MM</given-names></name><name><surname>Delpit</surname><given-names>E</given-names></name><etal/></person-group><year>2001</year><article-title>Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment.</article-title><source>J Clin Invest</source><volume>107</volume><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">11181650</pub-id></mixed-citation></ref><ref id="pone.0009629-Honeyborne2"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honeyborne</surname><given-names>I</given-names></name><name><surname>Rathod</surname><given-names>A</given-names></name><name><surname>Buchli</surname><given-names>R</given-names></name><name><surname>Ramduth</surname><given-names>D</given-names></name><name><surname>Moodley</surname><given-names>E</given-names></name><etal/></person-group><year>2006</year><article-title>Motif inference reveals optimal CTL epitopes presented by HLA class I alleles highly prevalent in southern Africa.</article-title><source>J Immunol</source><volume>176</volume><fpage>4699</fpage><lpage>4705</lpage><pub-id pub-id-type="pmid">16585563</pub-id></mixed-citation></ref><ref id="pone.0009629-Geldmacher1"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geldmacher</surname><given-names>C</given-names></name><name><surname>Currier</surname><given-names>JR</given-names></name><name><surname>Herrmann</surname><given-names>E</given-names></name><name><surname>Haule</surname><given-names>A</given-names></name><name><surname>Kuta</surname><given-names>E</given-names></name><etal/></person-group><year>2007</year><article-title>CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients.</article-title><source>J Virol</source><volume>81</volume><fpage>2440</fpage><lpage>2448</lpage><pub-id pub-id-type="pmid">17182686</pub-id></mixed-citation></ref><ref id="pone.0009629-Goepfert1"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goepfert</surname><given-names>PA</given-names></name><name><surname>Lumm</surname><given-names>W</given-names></name><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Matthews</surname><given-names>P</given-names></name><name><surname>Prendergast</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients.</article-title><source>J Exp Med</source><volume>205</volume><fpage>1009</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">18426987</pub-id></mixed-citation></ref><ref id="pone.0009629-Harrer1"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrer</surname><given-names>EG</given-names></name><name><surname>Bergmann</surname><given-names>S</given-names></name><name><surname>Eismann</surname><given-names>K</given-names></name><name><surname>Rittmaier</surname><given-names>M</given-names></name><name><surname>Goldwich</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>A conserved HLA B13-restricted cytotoxic T lymphocyte epitope in Nef is a dominant epitope in HLA B13-positive HIV-1-infected patients.</article-title><source>AIDS</source><volume>19</volume><fpage>734</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">15821402</pub-id></mixed-citation></ref><ref id="pone.0009629-Brumme3"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brumme</surname><given-names>ZL</given-names></name><name><surname>Brumme</surname><given-names>CJ</given-names></name><name><surname>Carlson</surname><given-names>J</given-names></name><name><surname>Streeck</surname><given-names>H</given-names></name><name><surname>John</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection.</article-title><source>J Virol</source><volume>82</volume><fpage>9216</fpage><lpage>9227</lpage><pub-id pub-id-type="pmid">18614631</pub-id></mixed-citation></ref><ref id="pone.0009629-Emu1"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emu</surname><given-names>B</given-names></name><name><surname>Sinclair</surname><given-names>E</given-names></name><name><surname>Hatano</surname><given-names>H</given-names></name><name><surname>Ferre</surname><given-names>A</given-names></name><name><surname>Shacklett</surname><given-names>B</given-names></name><etal/></person-group><year>2008</year><article-title>HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.</article-title><source>J Virol</source><volume>82</volume><fpage>5398</fpage><lpage>5407</lpage><pub-id pub-id-type="pmid">18353945</pub-id></mixed-citation></ref><ref id="pone.0009629-Prado1"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prado</surname><given-names>JG</given-names></name><name><surname>Honeyborne</surname><given-names>I</given-names></name><name><surname>Brierley</surname><given-names>I</given-names></name><name><surname>Puertas</surname><given-names>MC</given-names></name><name><surname>Martinez-Picado</surname><given-names>J</given-names></name><etal/></person-group><year>2009</year><article-title>Functional consequences of human immunodeficiency virus escape from an HLA-B&#x0002a;13-restricted CD8&#x0002b; T-cell epitope in p1 Gag protein.</article-title><source>J Virol</source><volume>83</volume><fpage>1018</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">18945768</pub-id></mixed-citation></ref><ref id="pone.0009629-Yu1"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Lichterfeld</surname><given-names>M</given-names></name><name><surname>Chetty</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>KL</given-names></name><name><surname>Mui</surname><given-names>SK</given-names></name><etal/></person-group><year>2007</year><article-title>Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes.</article-title><source>J Virol</source><volume>81</volume><fpage>1619</fpage><lpage>1631</lpage><pub-id pub-id-type="pmid">17121793</pub-id></mixed-citation></ref><ref id="pone.0009629-Karlsson1"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>AC</given-names></name><name><surname>Iversen</surname><given-names>AK</given-names></name><name><surname>Chapman</surname><given-names>JM</given-names></name><name><surname>de Oliviera</surname><given-names>T</given-names></name><name><surname>Spotts</surname><given-names>G</given-names></name><etal/></person-group><year>2007</year><article-title>Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape.</article-title><source>PLoS ONE</source><volume>2</volume><fpage>e225</fpage><pub-id pub-id-type="pmid">17311088</pub-id></mixed-citation></ref><ref id="pone.0009629-Crawford2"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>H</given-names></name><name><surname>Prado</surname><given-names>JG</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name><name><surname>Hue</surname><given-names>S</given-names></name><name><surname>Honeyborne</surname><given-names>I</given-names></name><etal/></person-group><year>2007</year><article-title>Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B&#x0002a;5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection.</article-title><source>J Virol</source><volume>81</volume><fpage>8346</fpage><lpage>8351</lpage><pub-id pub-id-type="pmid">17507468</pub-id></mixed-citation></ref><ref id="pone.0009629-Brenchley1"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name></person-group><year>2006</year><article-title>HIV disease: fallout from a mucosal catastrophe?</article-title><source>Nat Immunol</source><volume>7</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">16482171</pub-id></mixed-citation></ref><ref id="pone.0009629-Pellegrin1"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrin</surname><given-names>I</given-names></name><name><surname>Legrand</surname><given-names>E</given-names></name><name><surname>Neau</surname><given-names>D</given-names></name><name><surname>Bonot</surname><given-names>P</given-names></name><name><surname>Masquelier</surname><given-names>B</given-names></name><etal/></person-group><year>1996</year><article-title>Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.</article-title><source>J Acquir Immune Defic Syndr Hum Retrovirol</source><volume>11</volume><fpage>438</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">8605588</pub-id></mixed-citation></ref><ref id="pone.0009629-Kulkarni1"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>S</given-names></name><name><surname>Tripathy</surname><given-names>S</given-names></name><name><surname>Gangakhedkar</surname><given-names>R</given-names></name><name><surname>Jadhav</surname><given-names>S</given-names></name><name><surname>Agnihotri</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.</article-title><source>AIDS Res Hum Retroviruses</source><volume>24</volume><fpage>1159</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">18665801</pub-id></mixed-citation></ref><ref id="pone.0009629-Trask1"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trask</surname><given-names>SA</given-names></name><name><surname>Derdeyn</surname><given-names>CA</given-names></name><name><surname>Fideli</surname><given-names>U</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Meleth</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia.</article-title><source>J Virol</source><volume>76</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">11739704</pub-id></mixed-citation></ref><ref id="pone.0009629-Allen1"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>S</given-names></name><name><surname>Meinzen-Derr</surname><given-names>J</given-names></name><name><surname>Kautzman</surname><given-names>M</given-names></name><name><surname>Zulu</surname><given-names>I</given-names></name><name><surname>Trask</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Sexual behavior of HIV discordant couples after HIV counseling and testing.</article-title><source>AIDS</source><volume>17</volume><fpage>733</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">12646797</pub-id></mixed-citation></ref><ref id="pone.0009629-Kempf1"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempf</surname><given-names>MC</given-names></name><name><surname>Allen</surname><given-names>S</given-names></name><name><surname>Zulu</surname><given-names>I</given-names></name><name><surname>Kancheya</surname><given-names>N</given-names></name><name><surname>Stephenson</surname><given-names>R</given-names></name><etal/></person-group><year>2008</year><article-title>Enrollment and retention of HIV discordant couples in Lusaka, Zambia.</article-title><source>J Acquir Immune Defic Syndr</source><volume>47</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">18030162</pub-id></mixed-citation></ref><ref id="pone.0009629-Li1"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>W</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><etal/></person-group><year>2009</year><article-title>Clear and independent associations of several <italic>HLA-DRB1</italic> alleles with differential antibody responses to hepatitis B vaccination in youth.</article-title><source>Hum Genet</source><volume>126</volume><fpage>685</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">19597844</pub-id></mixed-citation></ref><ref id="pone.0009629-Robinson1"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Waller</surname><given-names>MJ</given-names></name><name><surname>Fail</surname><given-names>SC</given-names></name><name><surname>McWilliam</surname><given-names>H</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><etal/></person-group><year>2009</year><article-title>The IMGT/HLA database.</article-title><source>Nucleic Acids Res</source><volume>37</volume><fpage>D1013</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">18838392</pub-id></mixed-citation></ref><ref id="pone.0009629-Holdsworth1"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holdsworth</surname><given-names>R</given-names></name><name><surname>Hurley</surname><given-names>CK</given-names></name><name><surname>Marsh</surname><given-names>SG</given-names></name><name><surname>Lau</surname><given-names>M</given-names></name><name><surname>Noreen</surname><given-names>HJ</given-names></name><etal/></person-group><year>2009</year><article-title>The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens.</article-title><source>Tissue Antigens</source><volume>73</volume><fpage>95</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">19140825</pub-id></mixed-citation></ref><ref id="pone.0009629-Tang5"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>CM</given-names></name><name><surname>Meleth</surname><given-names>S</given-names></name><name><surname>Myracle</surname><given-names>A</given-names></name><name><surname>Lobashevsky</surname><given-names>E</given-names></name><etal/></person-group><year>2002</year><article-title>Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents.</article-title><source>AIDS</source><volume>16</volume><fpage>2275</fpage><lpage>2284</lpage><pub-id pub-id-type="pmid">12441799</pub-id></mixed-citation></ref><ref id="pone.0009629-Song1"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Ruder</surname><given-names>AM</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>R</given-names></name><etal/></person-group><year>2009</year><article-title>Genetic epidemiology of glioblastoma multiforme: Confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs.</article-title><source>PLoS One</source><volume>4</volume><fpage>e7157</fpage><pub-id pub-id-type="pmid">19774073</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by National Institute of Allergy and Infectious Diseases (NIAID), through grants AI040951 (to S.A.), AI071906 (to R.A.K.), and AI064060 (to E.H). J.T. is the recipient of an Independent Scientist Award (AI76123) from NIAID. The funders had no role in study design, data collection, data analyses, decision to publish, or preparation of this manuscript.</p></fn></fn-group></back></article>